Characterization	O
of	O
the	O
CD48	B-DNA
gene	I-DNA
demonstrates	O
a	O
positive	O
element	O
that	O
is	O
specific	O
to	O
Epstein-Barr	B-cell_type
virus-immortalized	I-cell_type
B-cell	I-cell_type
lines	I-cell_type
and	O
contains	O
an	O
essential	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
.	O

Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
infection	O
of	O
mature	O
,	O
resting	B-cell_type
B	I-cell_type
cells	I-cell_type
drives	O
them	O
to	O
become	O
lymphoblasts	O
expressing	O
high	O
levels	O
of	O
cell	O
surface	O
molecules	O
,	O
such	O
as	O
CD48	B-protein
,	O
characteristically	O
expressed	O
on	O
normal	B-cell_type
activated	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O

Here	O
,	O
we	O
report	O
on	O
the	O
identification	O
of	O
an	O
enhancer	B-DNA
element	I-DNA
in	O
the	O
CD48	B-DNA
gene	I-DNA
which	O
reproducibly	O
confers	O
strong	O
transcriptional	O
activity	O
only	O
in	O
EBV-positive	B-cell_line
B-lymphoblastoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

The	O
element	O
is	O
not	O
activated	O
upon	O
infection	O
of	O
established	O
EBV-negative	B-cell_line
B-cell	I-cell_line
lines	I-cell_line
,	O
indicating	O
that	O
EBV	O
fails	O
to	O
drive	O
these	O
cells	O
to	O
a	O
fully	O
lymphoblastoid	B-cell_type
phenotype	I-cell_type
.	O

An	O
NF-kappa	B-protein
B	I-protein
binding	O
site	O
is	O
an	O
essential	O
component	O
of	O
the	O
element	O
but	O
alone	O
is	O
not	O
sufficient	O
to	O
account	O
for	O
the	O
activity	O
or	O
the	O
specificity	O
of	O
the	O
element	O
.	O

We	O
have	O
detected	O
a	O
specific	O
nuclear	B-protein
protein	I-protein
complex	I-protein
that	O
binds	O
to	O
the	O
element	O
and	O
show	O
that	O
NF-kappa	B-protein
B1	I-protein
(	O
p50	B-protein
)	O
is	O
a	O
part	O
of	O
this	O
complex	O
.	O

The	O
EBV-encoded	B-protein
latent	I-protein
membrane	I-protein
protein	I-protein
1	I-protein
is	O
capable	O
of	O
transactivating	O
the	O
isolated	O
CD48	B-protein
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
but	O
not	O
the	O
intact	B-DNA
element	I-DNA
,	O
suggesting	O
that	O
the	O
latent	B-protein
membrane	I-protein
protein	I-protein
1	I-protein
-driven	O
activation	O
of	O
NF-kappa	B-protein
B/Rel	I-protein
must	O
interact	O
with	O
other	O
regulatory	O
pathways	O
to	O
control	O
expression	O
of	O
cellular	O
genes	O
as	O
EBV	O
drives	O
resting	B-cell_type
B	I-cell_type
cells	I-cell_type
into	O
the	O
cell	O
cycle	O
.	O

JOURNAL	NULL
OF	NULL
VIROLOGY	NULL
,	NULL
Feb.	NULL
1995	NULL
,	NULL
p.	NULL
871-881	NULL
0022-538	NULL
X/95/	NULL
$	NULL
04.00+0	NULL
Copyright	NULL
©	NULL
1995	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

69	NULL
,	NULL
No	NULL
.	NULL

2	NULL
Characterization	NULL
of	NULL
the	NULL
CD48	NULL
Gene	NULL
Demonstrates	NULL
a	NULL
Positive	NULL
Element	NULL
That	NULL
Is	NULL
Specific	NULL
to	NULL
Epstein-Barr	NULL
Virus-Immortalized	NULL
B-Cell	NULL
Lines	NULL
and	NULL
Contains	NULL
an	NULL
Essential	NULL
NF-KB	NULL
Site	NULL
LORI	NULL
D.	NULL
KLAMAN	NULL
anp	NULL
DAVID	NULL
A.	NULL
THORLEY-LAWSON®*	NULL
Department	NULL
of	NULL
Pathology	NULL
,	NULL
Tufts	NULL
University	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Boston	NULL
,	NULL
Massachusetts	NULL
02111	NULL
Received	NULL
1	NULL
September	NULL
1994/Accepted	NULL
31	NULL
October	NULL
1994	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
infection	NULL
of	NULL
mature	NULL
,	NULL
resting	NULL
B	NULL
cells	NULL
drives	NULL
them	NULL
to	NULL
become	NULL
lymphoblasts	NULL
expressing	NULL
high	NULL
levels	NULL
of	NULL
cell	NULL
surface	NULL
molecules	NULL
,	NULL
such	NULL
as	NULL
CD48	NULL
,	NULL
characteristically	NULL
expressed	NULL
on	NULL
normal	NULL
activated	NULL
B	NULL
cells	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
report	NULL
on	NULL
the	NULL
identification	NULL
of	NULL
an	NULL
enhancer	NULL
element	NULL
in	NULL
the	NULL
CD48	NULL
gene	NULL
which	NULL
reproducibly	NULL
confers	NULL
strong	NULL
transcriptional	NULL
activity	NULL
only	NULL
in	NULL
EBV-positive	NULL
B-lymphoblastoid	NULL
cell	NULL
lines	NULL
.	NULL

The	NULL
element	NULL
is	NULL
not	NULL
activated	NULL
upon	NULL
infection	NULL
of	NULL
established	NULL
EBV-negative	NULL
B-cell	NULL
lines	NULL
,	NULL
indicating	NULL
that	NULL
EBV	NULL
fails	NULL
to	NULL
drive	NULL
these	NULL
cells	NULL
to	NULL
a	NULL
fully	NULL
lymphoblastoid	NULL
phenotype	NULL
.	NULL

An	NULL
NF-KB	NULL
binding	NULL
site	NULL
is	NULL
an	NULL
essential	NULL
component	NULL
of	NULL
the	NULL
element	NULL
but	NULL
alone	NULL
is	NULL
not	NULL
sufficient	NULL
to	NULL
account	NULL
for	NULL
the	NULL
activity	NULL
or	NULL
the	NULL
specificity	NULL
of	NULL
the	NULL
element	NULL
.	NULL

We	NULL
have	NULL
detected	NULL
a	NULL
specific	NULL
nuclear	NULL
protein	NULL
complex	NULL
that	NULL
binds	NULL
to	NULL
the	NULL
element	NULL
and	NULL
show	NULL
that	NULL
NF-B1	NULL
(	NULL
p50	NULL
)	NULL
is	NULL
a	NULL
part	NULL
of	NULL
this	NULL
complex	NULL
.	NULL

The	NULL
EBV-encoded	NULL
latent	NULL
membrane	NULL
protein	NULL
1	NULL
is	NULL
capable	NULL
of	NULL
transactivating	NULL
the	NULL
isolated	NULL
CD48	NULL
NF-KB	NULL
site	NULL
but	NULL
not	NULL
the	NULL
intact	NULL
element	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
latent	NULL
membrane	NULL
protein	NULL
1-driven	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B/Rel	NULL
must	NULL
interact	NULL
with	NULL
other	NULL
regulatory	NULL
pathways	NULL
to	NULL
control	NULL
expression	NULL
of	NULL
cellular	NULL
genes	NULL
as	NULL
EBV	NULL
drives	NULL
resting	NULL
B	NULL
cells	NULL
into	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
is	NULL
a	NULL
B-lymphotropic	NULL
herpesvirus	NULL
that	NULL
is	NULL
associated	NULL
with	NULL
several	NULL
benign	NULL
and	NULL
neoplastic	NULL
diseases	NULL
in	NULL
humans	NULL
(	NULL
reviewed	NULL
in	NULL
references	NULL
11	NULL
and	NULL
29	NULL
)	NULL
.	NULL

EBV	NULL
infects	NULL
mature	NULL
,	NULL
resting	NULL
B	NULL
lymphocytes	NULL
in	NULL
vitro	NULL
,	NULL
causing	NULL
them	NULL
to	NULL
proliferate	NULL
indefinitely	NULL
(	NULL
33	NULL
)	NULL
,	NULL
a	NULL
process	NULL
that	NULL
has	NULL
been	NULL
termed	NULL
immortalization	NULL
or	NULL
growth	NULL
transformation	NULL
.	NULL

During	NULL
this	NULL
process	NULL
the	NULL
virus	NULL
expresses	NULL
nine	NULL
proteins	NULL
,	NULL
of	NULL
which	NULL
six	NULL
(	NULL
EBNA-1	NULL
to	NULL
-6	NULL
)	NULL
are	NULL
located	NULL
in	NULL
the	NULL
nucleus	NULL
and	NULL
three	NULL
(	NULL
latent	NULL
membrane	NULL
protein	NULL
1	NULL
[	NULL
LMP	NULL
-1	NULL
]	NULL
,	NULL
LMP	NULL
-2a	NULL
,	NULL
and	NULL
LMP-2b	NULL
)	NULL
are	NULL
located	NULL
in	NULL
the	NULL
membrane	NULL
.	NULL

Of	NULL
these	NULL
,	NULL
EBNA-1	NULL
,	NULL
-2	NULL
,	NULL
-3	NULL
,	NULL
and	NULL
-6	NULL
and	NULL
LMP	NULL
are	NULL
essential	NULL
for	NULL
growth	NULL
transformation	NULL
(	NULL
19	NULL
,	NULL
20	NULL
,	NULL
39	NULL
)	NULL
.	NULL

The	NULL
immortalized	NULL
cells	NULL
do	NULL
not	NULL
retain	NULL
the	NULL
surface	NULL
phenotype	NULL
of	NULL
resting	NULL
B	NULL
cells	NULL
.	NULL

Rather	NULL
,	NULL
they	NULL
express	NULL
elevated	NULL
levels	NULL
of	NULL
B-cell-associated	NULL
activation	NULL
antigens	NULL
and	NULL
adhesion	NULL
molecules	NULL
(	NULL
7	NULL
,	NULL
21	NULL
,	NULL
36-38	NULL
,	NULL
41	NULL
,	NULL
42	NULL
)	NULL
.	NULL

Pheno-typically	NULL
,	NULL
therefore	NULL
,	NULL
they	NULL
resemble	NULL
normal	NULL
B	NULL
cells	NULL
that	NULL
have	NULL
become	NULL
activated	NULL
in	NULL
response	NULL
to	NULL
antigen	NULL
or	NULL
mitogens	NULL
.	NULL

This	NULL
observation	NULL
led	NULL
to	NULL
the	NULL
suggestion	NULL
that	NULL
EBV	NULL
does	NULL
not	NULL
directly	NULL
immortalize	NULL
B	NULL
cells	NULL
but	NULL
achieves	NULL
this	NULL
through	NULL
two	NULL
distinct	NULL
processes	NULL
(	NULL
36	NULL
)	NULL
.	NULL

The	NULL
first	NULL
parallels	NULL
the	NULL
normal	NULL
differentiation	NULL
pathway	NULL
for	NULL
resting	NULL
B	NULL
cells	NULL
whereby	NULL
they	NULL
become	NULL
activated	NULL
,	NULL
proliferating	NULL
lymphoblasts	NULL
(	NULL
6	NULL
,	NULL
23	NULL
,	NULL
24	NULL
)	NULL
.	NULL

The	NULL
second	NULL
involves	NULL
arresting	NULL
the	NULL
cells	NULL
at	NULL
this	NULL
stage	NULL
,	NULL
so	NULL
that	NULL
they	NULL
can	NULL
not	NULL
terminally	NULL
differentiate	NULL
into	NULL
plasma	NULL
cells	NULL
,	NULL
resulting	NULL
in	NULL
continuous	NULL
proliferation	NULL
and	NULL
the	NULL
outgrowth	NULL
of	NULL
EBV-positive	NULL
(	NULL
EBV	NULL
*	NULL
)	NULL
B-lymphoblastoid	NULL
cell	NULL
lines	NULL
(	NULL
B-LCLs	NULL
)	NULL
.	NULL

It	NULL
follows	NULL
that	NULL
induction	NULL
of	NULL
the	NULL
lymphoblastoid	NULL
phenotype	NULL
is	NULL
an	NULL
essential	NULL
step	NULL
in	NULL
the	NULL
mechanism	NULL
by	NULL
which	NULL
EBV	NULL
immortalizes	NULL
resting	NULL
B	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
little	NULL
is	NULL
known	NULL
about	NULL
how	NULL
EBV	NULL
regulates	NULL
cellular	NULL
gene	NULL
expression	NULL
to	NULL
achieve	NULL
and	NULL
maintain	NULL
this	NULL
phenotype	NULL
.	NULL

Of	NULL
the	NULL
cellular	NULL
molecules	NULL
known	NULL
to	NULL
be	NULL
induced	NULL
by	NULL
EBV	NULL
,	NULL
only	NULL
CD23	NULL
has	NULL
been	NULL
characterized	NULL
at	NULL
the	NULL
level	NULL
of	NULL
transcription	NULL
(	NULL
22	NULL
,	NULL
26	NULL
,	NULL
43	NULL
)	NULL
.	NULL

Regulatory	NULL
regions	NULL
that	NULL
map	NULL
to	NULL
different	NULL
parts	NULL
of	NULL
the	NULL
gene	NULL
were	NULL
identified	NULL
,	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
Department	NULL
of	NULL
Pathology	NULL
,	NULL
Tufts	NULL
University	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
136	NULL
Harrison	NULL
Ave.	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
02111	NULL
.	NULL

Phone	NULL
:	NULL
(	NULL
617	NULL
)	NULL
636-4726	NULL
.	NULL

Fax	NULL
:	NULL
(	NULL
617	NULL
)	NULL
636-8590	NULL
.	NULL

871	NULL
but	NULL
the	NULL
minimal	NULL
elements	NULL
demonstrated	NULL
weak	NULL
transactivation	NULL
(	NULL
two-	NULL
to	NULL
fourfold	NULL
)	NULL
.	NULL

We	NULL
have	NULL
chosen	NULL
CD48	NULL
as	NULL
a	NULL
model	NULL
gene	NULL
to	NULL
address	NULL
these	NULL
issues	NULL
.	NULL

The	NULL
CD48	NULL
gene	NULL
encodes	NULL
an	NULL
adhesion	NULL
molecule	NULL
(	NULL
35	NULL
)	NULL
that	NULL
is	NULL
induced	NULL
to	NULL
high	NULL
levels	NULL
on	NULL
the	NULL
surface	NULL
of	NULL
normal	NULL
,	NULL
mature	NULL
,	NULL
resting	NULL
B	NULL
lymphocytes	NULL
upon	NULL
infection	NULL
with	NULL
EBV	NULL
.	NULL

Increased	NULL
protein	NULL
expression	NULL
on	NULL
the	NULL
lymphoblast	NULL
surface	NULL
is	NULL
paralleled	NULL
by	NULL
a	NULL
marked	NULL
increase	NULL
in	NULL
CD48	NULL
mRNA	NULL
(	NULL
45	NULL
)	NULL
and	NULL
remains	NULL
high	NULL
on	NULL
all	NULL
EBV	NULL
*	NULL
B-LCLs	NULL
.	NULL

The	NULL
CD48	NULL
gene	NULL
is	NULL
also	NULL
constitutively	NULL
expressed	NULL
in	NULL
a	NULL
wide	NULL
range	NULL
of	NULL
EBV~	NULL
lymphoid	NULL
tumor	NULL
lines	NULL
,	NULL
including	NULL
Burkitt	NULL
's	NULL
lymphomas	NULL
(	NULL
BLs	NULL
)	NULL
.	NULL

EBV	NULL
infection	NULL
of	NULL
these	NULL
cells	NULL
induces	NULL
only	NULL
a	NULL
modest	NULL
further	NULL
increase	NULL
of	NULL
CD48	NULL
mRNA	NULL
as	NULL
measured	NULL
by	NULL
RNase	NULL
protection	NULL
analysis	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
it	NULL
was	NULL
not	NULL
possible	NULL
to	NULL
map	NULL
EBV-responsive	NULL
elements	NULL
in	NULL
the	NULL
CD48	NULL
gene	NULL
by	NULL
using	NULL
these	NULL
cells	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
used	NULL
deletion	NULL
analysis	NULL
of	NULL
the	NULL
upstream	NULL
region	NULL
of	NULL
the	NULL
CD48	NULL
gene	NULL
to	NULL
show	NULL
that	NULL
this	NULL
gene	NULL
is	NULL
differentially	NULL
regulated	NULL
in	NULL
EBV	NULL
*	NULL
B-LCLs	NULL
and	NULL
EBV	NULL
~	NULL
lymphoid	NULL
tumor	NULL
lines	NULL
.	NULL

This	NULL
has	NULL
allowed	NULL
us	NULL
to	NULL
map	NULL
an	NULL
element	NULL
that	NULL
confers	NULL
strong	NULL
transcriptional	NULL
activity	NULL
only	NULL
in	NULL
mature	NULL
normal	NULL
B	NULL
cells	NULL
infected	NULL
with	NULL
EBV	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Plasmid	NULL
constructions	NULL
.	NULL

(	NULL
i	NULL
)	NULL
Serial	NULL
deletion	NULL
reporter	NULL
plasmids	NULL
.	NULL

Cloning	NULL
of	NULL
the	NULL
5'-flanking	NULL
region	NULL
of	NULL
the	NULL
human	NULL
CD48	NULL
gene	NULL
and	NULL
construction	NULL
of	NULL
the	NULL
1.58-kb	NULL
HindIII-NspI	NULL
CD48	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
construct	NULL
(	NULL
-1.58	NULL
CAT	NULL
)	NULL
has	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
13	NULL
)	NULL
.	NULL

The	NULL
CAT	NULL
construct	NULL
was	NULL
digested	NULL
with	NULL
HindIII	NULL
to	NULL
remove	NULL
sequences	NULL
between	NULL
-1580	NULL
and	NULL
-234	NULL
and	NULL
religated	NULL
to	NULL
obtain	NULL
deletion	NULL
construct	NULL
p-234	NULL
CAT	NULL
.	NULL

All	NULL
other	NULL
deletion	NULL
constructs	NULL
were	NULL
generated	NULL
from	NULL
the	NULL
intact	NULL
-1.58	NULL
CAT	NULL
reporter	NULL
gene	NULL
plasmid	NULL
by	NULL
using	NULL
a	NULL
Bluescript	NULL
exo/	NULL
Mung	NULL
kit	NULL
(	NULL
Stratagene	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
a	NULL
KpnI-Clel	NULL
double	NULL
digest	NULL
of	NULL
-1.58	NULL
CAT	NULL
provided	NULL
a	NULL
substrate	NULL
for	NULL
the	NULL
exonuclease	NULL
III	NULL
enzyme	NULL
,	NULL
which	NULL
digests	NULL
in	NULL
from	NULL
5	NULL
'	NULL
overhangs	NULL
.	NULL

The	NULL
shortened	NULL
plasmids	NULL
were	NULL
blunt	NULL
ended	NULL
with	NULL
mung	NULL
bean	NULL
nuclease	NULL
and	NULL
religated	NULL
with	NULL
T4	NULL
DNA	NULL
ligase	NULL
,	NULL
resulting	NULL
in	NULL
deletion	NULL
constructs	NULL
with	NULL
the	NULL
following	NULL
endpoints	NULL
:	NULL
-1,442	NULL
CAT	NULL
,	NULL
-1,245	NULL
CAT	NULL
,	NULL
-1,066	NULL
CAT	NULL
,	NULL
-999	NULL
CAT	NULL
,	NULL
-869	NULL
CAT	NULL
,	NULL
-599	NULL
CAT	NULL
,	NULL
-384	NULL
CAT	NULL
,	NULL
and	NULL
-110	NULL
CAT	NULL
.	NULL

All	NULL
deletion	NULL
constructs	NULL
were	NULL
confirmed	NULL
by	NULL
restriction	NULL
endonuclease	NULL
analysis	NULL
and	NULL
DNA	NULL
sequencing	NULL
using	NULL
the	NULL
dideoxy-chain	NULL
termination	NULL
method	NULL
(	NULL
U.S.	NULL
Biochemical	NULL
,	NULL
Cleveland	NULL
,	NULL
Ohio	NULL
)	NULL
.	NULL

(	NULL
ii	NULL
)	NULL
Transfection	NULL
control	NULL
plasmids	NULL
.	NULL

The	NULL
positive	NULL
control	NULL
pCMV/HTLV	NULL
CAT	NULL
was	NULL
obtained	NULL
from	NULL
I.	NULL
S.	NULL
Y.	NULL
Chen	NULL
(	NULL
5	NULL
)	NULL
.	NULL

The	NULL
negative	NULL
control	NULL
pSL1	NULL
CAT	NULL
was	NULL
872	NULL
KLAMAN	NULL
AND	NULL
THORLEY-LAWSON	NULL
described	NULL
previously	NULL
(	NULL
13	NULL
)	NULL
.	NULL

The	NULL
cotransfected	NULL
internal	NULL
control	NULL
construct	NULL
pCMV	NULL
B-galactosidase	NULL
was	NULL
obtained	NULL
from	NULL
G.	NULL
MacGregor	NULL
(	NULL
Baylor	NULL
University	NULL
,	NULL
Tex	NULL
.	NULL
)	NULL

.	NULL

The	NULL
LMP-1	NULL
expression	NULL
vector	NULL
pSV2	NULL
BNLF1	NULL
(	NULL
2	NULL
)	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Bill	NULL
Sugden	NULL
.	NULL

The	NULL
mutant	NULL
construct	NULL
mt	NULL
NFkB	NULL
TK	NULL
(	NULL
thymidine	NULL
kinase	NULL
)	NULL
contains	NULL
two	NULL
copies	NULL
of	NULL
a	NULL
mutated	NULL
upstream	NULL
regulatory	NULL
element	NULL
(	NULL
URE	NULL
)	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
from	NULL
the	NULL
murine	NULL
c-myc	NULL
gene	NULL
(	NULL
10	NULL
)	NULL
.	NULL

The	NULL
pCD48	NULL
NFB	NULL
TK	NULL
CAT	NULL
construct	NULL
was	NULL
prepared	NULL
by	NULL
digesting	NULL
the	NULL
URE	NULL
TK	NULL
CAT	NULL
construct	NULL
with	NULL
BemHI	NULL
,	NULL
which	NULL
should	NULL
drop	NULL
out	NULL
the	NULL
URE	NULL
sequences	NULL
,	NULL
and	NULL
inserting	NULL
two	NULL
copies	NULL
of	NULL
the	NULL
CD48	NULL
NF-xB	NULL
site	NULL
(	NULL
5	NULL
%	NULL
-GATCCTTTCA	NULL
TAAGGAAGGGGCTTTCCCCATTGG-3	NULL
'	NULL
)	NULL
.	NULL

The	NULL
site	NULL
,	NULL
with	NULL
terminal	NULL
BamHI	NULL
sites	NULL
for	NULL
cloning	NULL
,	NULL
and	NULL
its	NULL
complementary	NULL
sequence	NULL
were	NULL
synthesized	NULL
on	NULL
an	NULL
automated	NULL
DNA	NULL
synthesizer	NULL
(	NULL
Applied	NULL
Biosystems	NULL
)	NULL
.	NULL

The	NULL
mutant	NULL
and	NULL
wild-type	NULL
URE	NULL
TK	NULL
CAT	NULL
constructs	NULL
(	NULL
10	NULL
)	NULL
were	NULL
generously	NULL
supplied	NULL
by	NULL
Gail	NULL
Sonenshein	NULL
.	NULL

(	NULL
ili	NULL
)	NULL
Preparation	NULL
of	NULL
enhancer	NULL
constructs	NULL
.	NULL

Scrial	NULL
deletion	NULL
construct	NULL
-1,066	NULL
CAT	NULL
was	NULL
digested	NULL
with	NULL
BamHI	NULL
,	NULL
which	NULL
opens	NULL
the	NULL
plasmid	NULL
in	NULL
the	NULL
polylinker	NULL
region	NULL
of	NULL
the	NULL
Bluescript	NULL
KS+	NULL
plasmid	NULL
,	NULL
3	NULL
'	NULL
of	NULL
the	NULL
bacterial	NULL
CAT	NULL
gene	NULL
.	NULL

A	NULL
PCR-amplified	NULL
product	NULL
,	NULL
corresponding	NULL
to	NULL
human	NULL
CD48	NULL
upstream	NULL
sequences	NULL
from	NULL
-1245	NULL
to	NULL
-1066	NULL
,	NULL
was	NULL
engineered	NULL
with	NULL
BamHI	NULL
ends	NULL
and	NULL
subcloned	NULL
into	NULL
the	NULL
BemHI-di-gested	NULL
-1,066	NULL
CAT	NULL
vector	NULL
.	NULL

Enhancer	NULL
plasmids	NULL
were	NULL
checked	NULL
by	NULL
dideoxy	NULL
sequencing	NULL
to	NULL
eliminate	NULL
PCR-derived	NULL
errors	NULL
and	NULL
to	NULL
determine	NULL
the	NULL
sense	NULL
or	NULL
antisense	NULL
orientation	NULL
of	NULL
the	NULL
insert	NULL
.	NULL

All	NULL
plasmid	NULL
DNA	NULL
used	NULL
for	NULL
transfections	NULL
was	NULL
purified	NULL
with	NULL
Qiagen	NULL
maxicolumns	NULL
(	NULL
Qiagen	NULL
,	NULL
Studio	NULL
City	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

Oligonucleotides	NULL
.	NULL

A	NULL
34-bp	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
human	NULL
immunoglobulin	NULL
kappa	NULL
(	NULL
Ig	NULL
«	NULL
)	NULL
light-chain	NULL
NF-	NULL
«	NULL
B	NULL
consensus	NULL
sequence	NULL
(	NULL
5'-ATTCCCCCAG	NULL
AGGGGGATITCCAAGAGGCCACCT-3	NULL
'	NULL
)	NULL
and	NULL
a	NULL
corresponding	NULL
oligonucleotide	NULL
with	NULL
a	NULL
mutated	NULL
human	NULL
Igx	NULL
light-chain	NULL
NF-	NULL
«	NULL
B	NULL
consensus	NULL
sequence	NULL
(	NULL
5'-ATTCCCCCAGAGGCGGATTTCGAAGAGGCCACCT-3	NULL
'	NULL
)	NULL
were	NULL
synthesized	NULL
with	NULL
their	NULL
complementary	NULL
sequences	NULL
on	NULL
an	NULL
automated	NULL
DNA	NULL
synthesizer	NULL
(	NULL
Applied	NULL
Biosystems	NULL
)	NULL
and	NULL
annealed	NULL
.	NULL

A	NULL
double-stranded	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
mouse	NULL
Ig	NULL
light-chain	NULL
NF-	NULL
«	NULL
B	NULL
consensus	NULL
site	NULL
was	NULL
purchased	NULL
from	NULL
Promega	NULL
(	NULL
Madison	NULL
,	NULL
Wis.	NULL
)	NULL
.	NULL

Double-stranded	NULL
oligonucleotides	NULL
containing	NULL
the	NULL
EBNA-1	NULL
and	NULL
Oct-1	NULL
binding	NULL
sites	NULL
were	NULL
purchased	NULL
from	NULL
Pharmacia	NULL
(	NULL
Piscataway	NULL
,	NULL
N.J.	NULL
)	NULL
.	NULL

Annealed	NULL
oligonucleotides	NULL
were	NULL
end	NULL
labeled	NULL
with	NULL
y-*°P-labeled	NULL
deoxynucleoside	NULL
triphos-phates	NULL
and	NULL
purified	NULL
over	NULL
a	NULL
NucTrap	NULL
column	NULL
(	NULL
Stratagene	NULL
)	NULL
.	NULL

Site-directed	NULL
mutagenesis	NULL
.	NULL

Mutant	NULL
CAT	NULL
reporter	NULL
plasmids	NULL
were	NULL
made	NULL
with	NULL
the	NULL
Amersham	NULL
oligonucleotide-directed	NULL
in	NULL
vitro	NULL
mutagenesis	NULL
system	NULL
(	NULL
Amersham	NULL
,	NULL
Arlington	NULL
Heights	NULL
,	NULL
IL	NULL
.	NULL
)	NULL

,	NULL
with	NULL
some	NULL
modifications	NULL
.	NULL

The	NULL
Bluescript	NULL
phagemid	NULL
(	NULL
Stratagene	NULL
)	NULL
with	NULL
the	NULL
-1.58	NULL
CAT	NULL
sequences	NULL
was	NULL
used	NULL
in	NULL
place	NULL
of	NULL
recombinant	NULL
M13	NULL
as	NULL
the	NULL
single-stranded	NULL
DNA	NULL
template	NULL
.	NULL

-1.58	NULL
CAT	NULL
single-stranded	NULL
DNA	NULL
was	NULL
rescued	NULL
with	NULL
the	NULL
R408	NULL
helper	NULL
phage	NULL
by	NULL
using	NULL
a	NULL
protocol	NULL
supplied	NULL
by	NULL
Strat-agene	NULL
.	NULL

To	NULL
introduce	NULL
mutations	NULL
into	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
(	NULL
-1149	NULL
to	NULL
-1133	NULL
)	NULL
,	NULL
the	NULL
oligonucleotides	NULL
mutant	NULL
1	NULL
(	NULL
mtl	NULL
;	NULL
5-GGTTTCATAAGGAAGCGGCTTTGCC	NULL
CATTGCTGCTCAG-3	NULL
'	NULL
)	NULL
and	NULL
mt2	NULL
(	NULL
5	NULL
%	NULL
-GGTTTCATAAGGAATGGTCTTGCG	NULL
CCATTGCTGCTCAG-3	NULL
'	NULL
)	NULL
were	NULL
designed	NULL
with	NULL
consideration	NULL
to	NULL
the	NULL
reported	NULL
frequency	NULL
of	NULL
base	NULL
usage	NULL
at	NULL
each	NULL
position	NULL
of	NULL
the	NULL
consensus	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Cell	NULL
culture	NULL
.	NULL

The	NULL
EBV	NULL
*	NULL
B-LCL	NULL
X50-7	NULL
and	NULL
the	NULL
EBV	NULL
~	NULL
BL	NULL
cell	NULL
line	NULL
DG75	NULL
were	NULL
kind	NULL
gifts	NULL
of	NULL
Sam	NULL
Speck	NULL
(	NULL
Washington	NULL
University	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
Mo	NULL
.	NULL
)	NULL

.	NULL

The	NULL
EBV	NULL
*	NULL
B-LCL	NULL
[	NULL
B4	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Elliot	NULL
Kieff	NULL
(	NULL
Harvard	NULL
University	NULL
Medical	NULL
School	NULL
,	NULL
Boston	NULL
,	NULL
Mass	NULL
.	NULL
)	NULL

.	NULL

The	NULL
EBV	NULL
*	NULL
B-LCL	NULL
JY	NULL
was	NULL
previously	NULL
established	NULL
in	NULL
our	NULL
laboratory	NULL
.	NULL

The	NULL
EBV	NULL
~	NULL
BJAB	NULL
line	NULL
,	NULL
the	NULL
BL41	NULL
BL	NULL
line	NULL
,	NULL
and	NULL
their	NULL
EBV-converted	NULL
counterparts	NULL
BJAB	NULL
B95-8	NULL
and	NULL
BL41	NULL
B95-8	NULL
were	NULL
a	NULL
generous	NULL
gift	NULL
of	NULL
Gilbert	NULL
Lenoir	NULL
(	NULL
Lyon	NULL
,	NULL
France	NULL
)	NULL
.	NULL

The	NULL
helper	NULL
T-cell	NULL
line	NULL
Jurkat	NULL
,	NULL
the	NULL
erythroleukemic	NULL
cell	NULL
line	NULL
K562	NULL
,	NULL
and	NULL
the	NULL
fibroblast	NULL
line	NULL
HEL299	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
(	NULL
Rockville	NULL
,	NULL
Md	NULL
.	NULL
)	NULL

.	NULL

All	NULL
cell	NULL
lines	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
,	NULL
100	NULL
U	NULL
of	NULL
penicillin	NULL
per	NULL
ml	NULL
,	NULL
and	NULL
50	NULL
pg	NULL
of	NULL
streptomycin	NULL
per	NULL
ml	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
by	NULL
a	NULL
modification	NULL
of	NULL
the	NULL
Dignam	NULL
method	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Several	NULL
preparations	NULL
of	NULL
extract	NULL
were	NULL
isolated	NULL
and	NULL
tested	NULL
for	NULL
binding	NULL
activity	NULL
with	NULL
the	NULL
ubiquitous	NULL
Oct-1	NULL
binding	NULL
site	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
.	NULL

The	NULL
protein	NULL
concentration	NULL
of	NULL
the	NULL
nuclear	NULL
extract	NULL
was	NULL
assayed	NULL
by	NULL
the	NULL
Bradford	NULL
method	NULL
(	NULL
Bio-Rad	NULL
,	NULL
Hercules	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

Extracts	NULL
were	NULL
stored	NULL
at	NULL
-70°C	NULL
.	NULL

Transfection	NULL
of	NULL
cell	NULL
lines	NULL
.	NULL

With	NULL
the	NULL
exception	NULL
of	NULL
HEL299	NULL
,	NULL
all	NULL
cell	NULL
lines	NULL
were	NULL
transiently	NULL
transfected	NULL
by	NULL
electroporation	NULL
.	NULL

Transfections	NULL
of	NULL
HEL299	NULL
cells	NULL
were	NULL
performed	NULL
by	NULL
the	NULL
CaCl	NULL
,	NULL
method	NULL
(	NULL
16	NULL
)	NULL
.	NULL

For	NULL
each	NULL
electroporation	NULL
,	NULL
2	NULL
X	NULL
10	NULL
``	NULL
cells	NULL
were	NULL
washed	NULL
once	NULL
in	NULL
phosphate-buffered	NULL
saline	NULL
,	NULL
resuspended	NULL
in	NULL
0.5	NULL
ml	NULL
of	NULL
Gibco	NULL
Optimem	NULL
,	NULL
and	NULL
transferred	NULL
to	NULL
a	NULL
Bio-Rad	NULL
Gene	NULL
Pulser	NULL
cuvette	NULL
containing	NULL
20	NULL
ug	NULL
of	NULL
CAT	NULL
reporter	NULL
gene	NULL
construct	NULL
DNA	NULL
and	NULL
5	NULL
pg	NULL
of	NULL
pCMV	NULL
B-galactosidase	NULL
DNA	NULL
,	NULL
an	NULL
internal	NULL
control	NULL
plasmid	NULL
included	NULL
to	NULL
monitor	NULL
transfection	NULL
efficiency	NULL
.	NULL

For	NULL
cotrans-fection	NULL
experiments	NULL
,	NULL
10	NULL
pg	NULL
of	NULL
reporter	NULL
construct	NULL
was	NULL
mixed	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
the	NULL
cotransfected	NULL
expression	NULL
vector	NULL
.	NULL

Cells	NULL
and	NULL
DNA	NULL
were	NULL
mixed	NULL
gently	NULL
,	NULL
and	NULL
the	NULL
cuvette	NULL
was	NULL
placed	NULL
on	NULL
ice	NULL
for	NULL
10	NULL
min	NULL
immediately	NULL
preceding	NULL
and	NULL
following	NULL
electroporation	NULL
in	NULL
a	NULL
Bio-Rad	NULL
Gene	NULL
Pulser	NULL
.	NULL

Optimal	NULL
transfection	NULL
conditions	NULL
for	NULL
each	NULL
cell	NULL
line	NULL
were	NULL
determined	NULL
by	NULL
using	NULL
the	NULL
positive	NULL
control	NULL
pCMV/HTLV	NULL
CAT	NULL
.	NULL

Analysis	NULL
of	NULL
transfected	NULL
cells	NULL
.	NULL

Cell	NULL
lysates	NULL
were	NULL
harvested	NULL
48	NULL
h	NULL
posttransfection	NULL
,	NULL
resuspended	NULL
in	NULL
250	NULL
mM	NULL
Tris-HCI	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
,	NULL
and	NULL
subjected	NULL
to	NULL
three	NULL
freeze-thaw	NULL
cycles	NULL
with	NULL
liquid	NULL
N	NULL
;	NULL
.	NULL

Cell	NULL
lysates	NULL
,	NULL
normalized	NULL
for	NULL
protein	NULL
concentration	NULL
(	NULL
Brad-ford	NULL
dye	NULL
reagent	NULL
kit	NULL
;	NULL
Bio-Rad	NULL
)	NULL
,	NULL
were	NULL
used	NULL
to	NULL
assay	NULL
transfection	NULL
efficiencies	NULL
in	NULL
a	NULL
B-galactosidase	NULL
assay	NULL
(	NULL
34	NULL
)	NULL
.	NULL

For	NULL
individual	NULL
CAT	NULL
assays	NULL
,	NULL
equal	NULL
B-galactosidase	NULL
units	NULL
were	NULL
incubated	NULL
in	NULL
a	NULL
total	NULL
volume	NULL
of	NULL
150	NULL
pl	NULL
containing	NULL
250	NULL
mM	NULL
Tris-HCl	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
,	NULL
68	NULL
uM	NULL
acetyl	NULL
coenzyme	NULL
A	NULL
,	NULL
and	NULL
0.05	NULL
Ci	NULL
of	NULL
[	NULL
'*CJchloramphenicol	NULL
for	NULL
2	NULL
h	NULL
at	NULL
37°C	NULL
.	NULL

CAT	NULL
activity	NULL
was	NULL
assayed	NULL
by	NULL
the	NULL
standard	NULL
method	NULL
of	NULL
Gorman	NULL
et	NULL
al	NULL
.	NULL

(	NULL
15	NULL
)	NULL
.	NULL

Acetylated	NULL
and	NULL
nonacetylated	NULL
[	NULL
'*CJchloramphenicol	NULL
activity	NULL
was	NULL
quanti-tated	NULL
by	NULL
analyzing	NULL
the	NULL
thin-layer	NULL
chromatographic	NULL
plates	NULL
following	NULL
exposure	NULL
to	NULL
PhosphorImager	NULL
screens	NULL
(	NULL
Molecular	NULL
Dynamics	NULL
,	NULL
Sunnyvale	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

J.	NULL
ViRor	NULL
.	NULL

EMSA	NULL
.	NULL

For	NULL
protein-DNA	NULL
binding	NULL
reactions	NULL
,	NULL
5	NULL
ug	NULL
of	NULL
nuclear	NULL
extract	NULL
was	NULL
mixed	NULL
with	NULL
1.5	NULL
jg	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
in	NULL
a	NULL
total	NULL
volume	NULL
of	NULL
20	NULL
pl	NULL
consisting	NULL
of	NULL
10	NULL
mM	NULL
Tris-HCl	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
,	NULL
50	NULL
mM	NULL
NaCl	NULL
,	NULL
10	NULL
%	NULL
glycerol	NULL
,	NULL
0.05	NULL
%	NULL
Nonidet	NULL
P-40	NULL
,	NULL
5	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
0.5	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
and	NULL
0.5	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
.	NULL

Following	NULL
the	NULL
addition	NULL
of	NULL
1.0	NULL
ng	NULL
of	NULL
«	NULL
-*	NULL
``	NULL
P-end-labeled	NULL
DNA	NULL
probe	NULL
(	NULL
~20,000	NULL
cpm	NULL
)	NULL
,	NULL
the	NULL
reaction	NULL
mixtures	NULL
were	NULL
incubated	NULL
for	NULL
20	NULL
min	NULL
at	NULL
25°C	NULL
.	NULL

Where	NULL
indicated	NULL
,	NULL
a	NULL
25-	NULL
to	NULL
200-fold	NULL
molar	NULL
excess	NULL
of	NULL
unlabeled	NULL
competitor	NULL
DNA	NULL
or	NULL
unrelated	NULL
DNA	NULL
was	NULL
added	NULL
10	NULL
min	NULL
prior	NULL
to	NULL
the	NULL
addition	NULL
of	NULL
the	NULL
labeled	NULL
probe	NULL
.	NULL

The	NULL
reaction	NULL
products	NULL
were	NULL
resolved	NULL
on	NULL
5	NULL
%	NULL
nondenaturing	NULL
polyacrylamide	NULL
gels	NULL
(	NULL
40:1	NULL
cross-linking	NULL
ratio	NULL
;	NULL
in	NULL
0.5	NULL
%	NULL
Tris-glycine	NULL
at	NULL
4°C	NULL
)	NULL
.	NULL

For	NULL
supershifting	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
(	NULL
EMSAs	NULL
)	NULL
,	NULL
binding	NULL
reaction	NULL
mixtures	NULL
were	NULL
incubated	NULL
with	NULL
1	NULL
pl	NULL
(	NULL
per	NULL
5	NULL
pg	NULL
of	NULL
nuclear	NULL
extract	NULL
)	NULL
of	NULL
the	NULL
appropriate	NULL
antisera	NULL
,	NULL
or	NULL
a	NULL
preimmune	NULL
control	NULL
,	NULL
for	NULL
20	NULL
min	NULL
at	NULL
4°C	NULL
prior	NULL
to	NULL
the	NULL
addition	NULL
of	NULL
the	NULL
end-labeled	NULL
probe	NULL
.	NULL

NF-	NULL
«	NULL
B1	NULL
(	NULL
p50	NULL
)	NULL
,	NULL
RelA	NULL
(	NULL
p65	NULL
)	NULL
,	NULL
and	NULL
c-ref	NULL
supershifting	NULL
antisera	NULL
were	NULL
generously	NULL
supplied	NULL
by	NULL
Nancy	NULL
Rice	NULL
(	NULL
Frederick	NULL
,	NULL
Md	NULL
.	NULL
)	NULL

and	NULL
Uli	NULL
Sicbenlist	NULL
(	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Bethesda	NULL
,	NULL
Md	NULL
.	NULL
)	NULL

.	NULL

DNase	NULL
I	NULL
footprinting	NULL
.	NULL

For	NULL
DNase	NULL
I	NULL
protection	NULL
assays	NULL
,	NULL
probes	NULL
were	NULL
incubated	NULL
with	NULL
nuclear	NULL
extract	NULL
in	NULL
a	NULL
reaction	NULL
mixture	NULL
that	NULL
had	NULL
been	NULL
scaled	NULL
up	NULL
fivefold	NULL
from	NULL
the	NULL
EMSA	NULL
binding	NULL
reaction	NULL
.	NULL

The	NULL
mixture	NULL
was	NULL
digested	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
DNase	NULL
I	NULL
per	NULL
ml	NULL
for	NULL
2	NULL
min	NULL
at	NULL
25°C	NULL
.	NULL

Equal	NULL
counts	NULL
per	NULL
minute	NULL
of	NULL
bound	NULL
and	NULL
free	NULL
samples	NULL
were	NULL
resolved	NULL
on	NULL
an	NULL
8	NULL
%	NULL
polyacrylamide-8	NULL
M	NULL
urea	NULL
sequencing	NULL
gel	NULL
.	NULL

Footprint	NULL
data	NULL
were	NULL
obtained	NULL
on	NULL
both	NULL
strands	NULL
and	NULL
the	NULL
positions	NULL
of	NULL
the	NULL
protected	NULL
regions	NULL
were	NULL
determined	NULL
by	NULL
reference	NULL
to	NULL
a	NULL
G+	NULL
A	NULL
Maxam-Gilbert	NULL
ladder	NULL
(	NULL
28	NULL
)	NULL
resolved	NULL
in	NULL
parallel	NULL
.	NULL

RESULTS	NULL
CD48	NULL
5'-flanking	NULL
sequences	NULL
that	NULL
regulate	NULL
responsiveness	NULL
in	NULL
EBV	NULL
*	NULL
B-LCLs	NULL
.	NULL

A	NULL
CAT	NULL
reporter	NULL
gene	NULL
construct	NULL
(	NULL
-1.58	NULL
CAT	NULL
)	NULL
containing	NULL
1.58	NULL
kb	NULL
of	NULL
sequences	NULL
5	NULL
'	NULL
of	NULL
the	NULL
transcriptional	NULL
start	NULL
sites	NULL
of	NULL
the	NULL
CD48	NULL
gene	NULL
has	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
13	NULL
)	NULL
.	NULL

A	NULL
series	NULL
of	NULL
5	NULL
``	NULL
deletions	NULL
were	NULL
derived	NULL
from	NULL
-1.58	NULL
CAT	NULL
,	NULL
and	NULL
their	NULL
structures	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

These	NULL
constructs	NULL
were	NULL
transiently	NULL
transfected	NULL
into	NULL
a	NULL
panel	NULL
of	NULL
EBV	NULL
*	NULL
and	NULL
EBV~	NULL
cell	NULL
lines	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
to	NULL
localize	NULL
transcriptional	NULL
elements	NULL
that	NULL
regulate	NULL
expression	NULL
of	NULL
the	NULL
CD48	NULL
gene	NULL
.	NULL

Relative	NULL
activities	NULL
of	NULL
the	NULL
deletion	NULL
constructs	NULL
are	NULL
displayed	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
for	NULL
1B4	NULL
and	NULL
BJAB	NULL
,	NULL
representative	NULL
of	NULL
EBV	NULL
*	NULL
B-LCLs	NULL
and	NULL
EBV	NULL
~	NULL
lymphoid	NULL
cell	NULL
lines	NULL
,	NULL
respectively	NULL
.	NULL

Data	NULL
for	NULL
the	NULL
most	NULL
important	NULL
constructs	NULL
(	NULL
-1.58	NULL
CAT	NULL
and	NULL
-869	NULL
CAT	NULL
)	NULL
are	NULL
presented	NULL
,	NULL
for	NULL
all	NULL
cell	NULL
lines	NULL
tested	NULL
,	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

The	NULL
largest	NULL
deletion	NULL
with	NULL
consistently	NULL
high	NULL
reporter	NULL
gene	NULL
activity	NULL
was	NULL
-234	NULL
CAT	NULL
.	NULL

This	NULL
construct	NULL
had	NULL
promoter	NULL
activity	NULL
that	NULL
reflected	NULL
the	NULL
behavior	NULL
of	NULL
the	NULL
endogenous	NULL
CD48	NULL
gene	NULL
.	NULL

It	NULL
was	NULL
active	NULL
in	NULL
B-	NULL
and	NULL
T-cell	NULL
lines	NULL
irrespective	NULL
of	NULL
EBV	NULL
status	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
but	NULL
not	NULL
in	NULL
nonlymphoid	NULL
lines	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
suggesting	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
lymphoid	NULL
cell-restricted	NULL
proximal	NULL
element	NULL
.	NULL

Constructs	NULL
with	NULL
smaller	NULL
deletions	NULL
showed	NULL
progressively	NULL
weaker	NULL
activity	NULL
until	NULL
-869	NULL
CAT	NULL
,	NULL
which	NULL
displayed	NULL
only	NULL
basal	NULL
levels	NULL
of	NULL
activity	NULL
in	NULL
all	NULL
cell	NULL
lines	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

In	NULL
the	NULL
case	NULL
of	NULL
the	NULL
EBV~	NULL
cell	NULL
lines	NULL
,	NULL
the	NULL
trend	NULL
continued	NULL
such	NULL
that	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
undeleted	NULL
-1.58	NULL
CAT	NULL
in	NULL
these	NULL
cells	NULL
was	NULL
indistinguishable	NULL
from	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
negative	NULL
control	NULL
(	NULL
pSL1	NULL
CAT	NULL
)	NULL
construct	NULL
.	NULL

However	NULL
,	NULL
in	NULL
the	NULL
case	NULL
of	NULL
the	NULL
EBV	NULL
*	NULL
B-LCLs	NULL
,	NULL
the	NULL
trend	NULL
was	NULL
dramatically	NULL
reversed	NULL
such	NULL
that	NULL
the	NULL
activity	NULL
of	NULL
-1.58	NULL
CAT	NULL
was	NULL
even	NULL
higher	NULL
than	NULL
that	NULL
obtained	NULL
with	NULL
-234	NULL
CAT	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

Within	NULL
a	NULL
given	NULL
experiment	NULL
,	NULL
activations	NULL
of	NULL
15-	NULL
to	NULL
75-fold	NULL
were	NULL
seen	NULL
when	NULL
we	NULL
compared	NULL
-1.58	NULL
CAT	NULL
and	NULL
-869	NULL
CAT	NULL
in	NULL
the	NULL
TABLE	NULL
1	NULL
.	NULL

EBV	NULL
*	NULL
and	NULL
EBV~	NULL
cell	NULL
lines	NULL
used	NULL
EBV	NULL
status	NULL
Cell	NULL
line	NULL
Cell	NULL
type	NULL
+	NULL
IB4	NULL
B	NULL
lymphoblast	NULL
JY	NULL
B	NULL
lymphoblast	NULL
X50-7	NULL
B	NULL
lymphoblast	NULL
-	NULL
DG75	NULL
B	NULL
lymphoma	NULL
(	NULL
Burkitt	NULL
)	NULL
BL41	NULL
B	NULL
lymphoma	NULL
(	NULL
Burkitt	NULL
)	NULL
BJAB	NULL
B	NULL
lymphoma	NULL
Jurkat	NULL
T	NULL
leukemia	NULL
K562	NULL
Erythroleukemia	NULL
HEL299	NULL
Fibroblast	NULL
Vou	NULL
.	NULL

69	NULL
,	NULL
1995	NULL
CD48	NULL
GENE	NULL
REGULATION	NULL
IN	NULL
EBV-IMMORTALIZED	NULL
B	NULL
CELLS	NULL
873	NULL
Hind	NULL
IM	NULL
Nsp	NULL
I	NULL
A	NULL
B	NULL
1,580	NULL
999	NULL
EX	NULL
1	NULL
-	NULL
INT	NULL
1	NULL
%	NULL
‘	NULL
CcMvHTLV	NULL
cat	NULL
wa	NULL
sii	NULL
cat	NULL
cat	NULL
Q	NULL
__	NULL
.isscar	NULL
-	NULL
_-~	NULL
c	NULL
1	NULL
0	NULL
«	NULL
sso	NULL
cat	NULL
_	NULL
MWH	NULL
E	NULL
0	NULL
-869	NULL
CAT	NULL
.	NULL
'	NULL

I	NULL
.	NULL

%	NULL
+384	NULL
CAT	NULL
8	NULL
%	NULL
234	NULL
CAT	NULL
P	NULL
&	NULL
-o	NULL
cat	NULL
-x	NULL
W	NULL
*	NULL
t	NULL
!	NULL

0	NULL
gw	NULL
»	NULL
$	NULL
sL1	NULL
cat	NULL
CAT	NULL
0	NULL
asscat	NULL
.	NULL

a	NULL
®	NULL
«	NULL
999	NULL
cat	NULL
CAT	NULL
_	NULL
]	NULL
I	NULL
A	NULL
®	NULL
sso	NULL
car	NULL
°	NULL
e	NULL
soo	NULL
cat	NULL
--	NULL
-Lca	NULL
)	NULL
WH	NULL
]	NULL
384	NULL
CAT	NULL
e	NULL
$	NULL
_	NULL
anos	NULL
-C	NULL
roo	NULL
:	NULL
ro-	NULL
r	NULL
r	NULL
A	NULL
A	NULL
A	NULL
0.0	NULL
0.5	NULL
1.0	NULL
CM	NULL
_	NULL
1AC-CM	NULL
3AC-CM	NULL
Relative	NULL
CAT	NULL
Activity	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Mapping	NULL
of	NULL
the	NULL
EBV-responsive	NULL
element	NULL
.	NULL

Regulatory	NULL
sequences	NULL
within	NULL
the	NULL
HindIII-NspI	NULL
CD48	NULL
genomic	NULL
fragment	NULL
were	NULL
mapped	NULL
by	NULL
measuring	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
-1.58	NULL
CAT	NULL
and	NULL
deletion	NULL
plasmids	NULL
,	NULL
using	NULL
various	NULL
lengths	NULL
of	NULL
the	NULL
5'-flanking	NULL
region	NULL
to	NULL
drive	NULL
transcription	NULL
of	NULL
CAT	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Transient	NULL
transfection	NULL
results	NULL
for	NULL
an	NULL
EBV	NULL
*	NULL
and	NULL
EBV~	NULL
cell	NULL
lines	NULL
,	NULL
IB4	NULL
and	NULL
BJAB	NULL
,	NULL
respectively	NULL
.	NULL

A	NULL
total	NULL
of	NULL
three	NULL
independent	NULL
transfection	NULL
experiments	NULL
were	NULL
performed	NULL
in	NULL
duplicate	NULL
for	NULL
each	NULL
cell	NULL
line	NULL
,	NULL
with	NULL
a	NULL
representative	NULL
assay	NULL
shown	NULL
.	NULL

Acetylated	NULL
(	NULL
1AC-CM	NULL
and	NULL
3AC-CM	NULL
)	NULL
and	NULL
unacetylated	NULL
(	NULL
CM	NULL
)	NULL
forms	NULL
of	NULL
[	NULL
**CJchloramphenicol	NULL
are	NULL
indicated	NULL
by	NULL
arrows	NULL
at	NULL
the	NULL
bottom	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Structure	NULL
of	NULL
the	NULL
HindIII-NspI	NULL
CD48	NULL
genomic	NULL
DNA	NULL
fragment	NULL
.	NULL

The	NULL
thick	NULL
bar	NULL
indicating	NULL
the	NULL
region	NULL
which	NULL
contains	NULL
the	NULL
EBV-responsive	NULL
element	NULL
as	NULL
defined	NULL
by	NULL
crude	NULL
deletion	NULL
mapping	NULL
of	NULL
CD48	NULL
CAT	NULL
plasmids	NULL
.	NULL

Ex	NULL
1	NULL
,	NULL
exon	NULL
1	NULL
;	NULL
INT	NULL
1	NULL
,	NULL
intron	NULL
1	NULL
.	NULL

A	NULL
schematic	NULL
view	NULL
of	NULL
the	NULL
5'-flanking	NULL
sequence	NULL
is	NULL
shown	NULL
for	NULL
each	NULL
CAT	NULL
construct	NULL
,	NULL
including	NULL
the	NULL
positive	NULL
control	NULL
and	NULL
negative	NULL
control	NULL
plasmids	NULL
,	NULL
pCMV/HTLV	NULL
CAT	NULL
and	NULL
pSL1	NULL
CAT	NULL
,	NULL
respectively	NULL
.	NULL

pCMV/HTLV	NULL
CAT	NULL
activity	NULL
is	NULL
assigned	NULL
an	NULL
arbitrary	NULL
value	NULL
of	NULL
1.0	NULL
.	NULL

The	NULL
bar	NULL
graph	NULL
shows	NULL
quantitation	NULL
of	NULL
relative	NULL
CAT	NULL
activity	NULL
following	NULL
transfection	NULL
of	NULL
-1.58	NULL
CAT	NULL
or	NULL
CD48	NULL
deletion	NULL
constructs	NULL
into	NULL
IB4	NULL
and	NULL
BJAB	NULL
.	NULL

same	NULL
EBV	NULL
*	NULL
B-LCL	NULL
or	NULL
compared	NULL
-1.58	NULL
CAT	NULL
between	NULL
an	NULL
positive	NULL
elements	NULL
,	NULL
not	NULL
present	NULL
in	NULL
this	NULL
construct	NULL
,	NULL
to	NULL
account	NULL
for	NULL
EBV	NULL
*	NULL
B-LCL	NULL
and	NULL
an	NULL
EBV~	NULL
cell	NULL
line	NULL
.	NULL

These	NULL
experiments	NULL
demonstrate	NULL
that	NULL
the	NULL
CD48	NULL
promoter	NULL
is	NULL
negatively	NULL
regulated	NULL
in	NULL
lymphoid	NULL
cell	NULL
lines	NULL
,	NULL
by	NULL
elements	NULL
located	NULL
between	NULL
positions	NULL
-234	NULL
and	NULL
-869	NULL
.	NULL

These	NULL
silencers	NULL
can	NULL
be	NULL
overcome	NULL
by	NULL
an	NULL
element	NULL
that	NULL
lies	NULL
further	NULL
upstream	NULL
(	NULL
between	NULL
-1580	NULL
and	NULL
-999	NULL
)	NULL
.	NULL

Because	NULL
this	NULL
element	NULL
specifically	NULL
functions	NULL
only	NULL
in	NULL
EBV	NULL
*	NULL
B-LCLs	NULL
,	NULL
we	NULL
refer	NULL
to	NULL
it	NULL
as	NULL
EBV	NULL
responsive	NULL
.	NULL

Since	NULL
the	NULL
endogenous	NULL
CD48	NULL
gene	NULL
is	NULL
also	NULL
active	NULL
in	NULL
EBV~	NULL
lymphoid	NULL
tumor	NULL
lines	NULL
but	NULL
-1.58	NULL
CAT	NULL
is	NULL
not	NULL
,	NULL
there	NULL
must	NULL
be	NULL
additional	NULL
CD48	NULL
gene	NULL
expression	NULL
in	NULL
the	NULL
EBV~	NULL
lymphoid	NULL
tumor	NULL
lines	NULL
.	NULL

The	NULL
CD48	NULL
EBV-responsive	NULL
element	NULL
is	NULL
an	NULL
enhancer	NULL
.	NULL

We	NULL
constructed	NULL
a	NULL
finer	NULL
set	NULL
of	NULL
deletion	NULL
mutants	NULL
between	NULL
-1.58	NULL
CAT	NULL
and	NULL
-869	NULL
CAT	NULL
to	NULL
more	NULL
precisely	NULL
map	NULL
the	NULL
boundaries	NULL
of	NULL
the	NULL
EBV-responsive	NULL
element	NULL
.	NULL

The	NULL
CAT	NULL
assay	NULL
for	NULL
this	NULL
set	NULL
of	NULL
deletion	NULL
mutants	NULL
is	NULL
shown	NULL
for	NULL
[	NULL
B4	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
and	NULL
is	NULL
representative	NULL
of	NULL
all	NULL
EBV	NULL
*	NULL
B-LCLs	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Deletion	NULL
constructs	NULL
up	NULL
to	NULL
-1,245	NULL
CAT	NULL
demonstrated	NULL
activity	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
-1.58	NULL
CAT	NULL
,	NULL
but	NULL
the	NULL
next	NULL
deletion	NULL
,	NULL
-1,066	NULL
CAT	NULL
,	NULL
and	NULL
subsequent	NULL
874	NULL
KLAMAN	NULL
AND	NULL
THORLEY-LAWSON	NULL
J.	NULL
ViroL	NULL
.	NULL

A	NULL
Hind	NULL
III	NULL
Nsp	NULL
I	NULL
__	NULL
]	NULL
|	NULL
;	NULL
»	NULL
~1,580	NULL
EX	NULL
1	NULL
INT	NULL
1	NULL
[	NULL
cat	NULL
]	NULL
1.53	NULL
cat	NULL
CAT	NULL
-869	NULL
CAT	NULL
1B4	NULL
JY	NULL
X50-7	NULL
DGT5S	NULL
BL41	NULL
BJAB	NULL
Cell	NULL
Line	NULL
Jurkat	NULL
K562	NULL
HEL299	NULL
m	NULL
~.58	NULL
cat	NULL
CQ	NULL
-s69	NULL
cat	NULL
0.6	NULL
0.8	NULL
1.0	NULL
1.2	NULL
Relative	NULL
CAT	NULL
Activity	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Demonstration	NULL
of	NULL
an	NULL
EBV-responsive	NULL
element	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Structure	NULL
of	NULL
the	NULL
HindIII-NspI	NULL
CD48	NULL
genomic	NULL
DNA	NULL
fragment	NULL
,	NULL
extending	NULL
1,580	NULL
bp	NULL
upstream	NULL
of	NULL
the	NULL
translational	NULL
start	NULL
site	NULL
of	NULL
exon	NULL
1	NULL
(	NULL
EX	NULL
1	NULL
)	NULL
,	NULL
used	NULL
to	NULL
construct	NULL
-1.58	NULL
CAT	NULL
.	NULL

INT	NULL
1	NULL
,	NULL
intron	NULL
1	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Quantitative	NULL
comparison	NULL
of	NULL
relative	NULL
CAT	NULL
activities	NULL
following	NULL
transient	NULL
transfection	NULL
of	NULL
-1.58	NULL
CAT	NULL
or	NULL
deletion	NULL
construct	NULL
-869	NULL
CAT	NULL
into	NULL
EBV	NULL
*	NULL
B-LCLs	NULL
and	NULL
EBV~	NULL
cell	NULL
lines	NULL
(	NULL
see	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

The	NULL
percentage	NULL
of	NULL
[	NULL
**C	NULL
]	NULL
chloramphenicol	NULL
conversion	NULL
is	NULL
reported	NULL
relative	NULL
to	NULL
that	NULL
of	NULL
the	NULL
positive	NULL
control	NULL
construct	NULL
pCMV/HTLV	NULL
CAT	NULL
,	NULL
which	NULL
is	NULL
assigned	NULL
an	NULL
arbitrary	NULL
value	NULL
of	NULL
1.0	NULL
.	NULL

Upper	NULL
axis	NULL
,	NULL
scale	NULL
for	NULL
1B4	NULL
;	NULL
lower	NULL
axis	NULL
,	NULL
scale	NULL
for	NULL
all	NULL
other	NULL
cell	NULL
lines	NULL
.	NULL

Reported	NULL
values	NULL
represent	NULL
the	NULL
means	NULL
and	NULL
standard	NULL
deviations	NULL
from	NULL
three	NULL
independent	NULL
experiments	NULL
each	NULL
in	NULL
duplicate	NULL
.	NULL

deletions	NULL
displayed	NULL
a	NULL
>	NULL
10-fold	NULL
drop	NULL
in	NULL
CAT	NULL
activity	NULL
and	NULL
were	NULL
indistinguishable	NULL
from	NULL
-869	NULL
CAT	NULL
.	NULL

None	NULL
of	NULL
the	NULL
deletion	NULL
mutants	NULL
in	NULL
this	NULL
set	NULL
displayed	NULL
detectable	NULL
CAT	NULL
activity	NULL
in	NULL
the	NULL
EBV~	NULL
cell	NULL
lines	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
experiment	NULL
localized	NULL
the	NULL
EBV-responsive	NULL
element	NULL
between	NULL
positions	NULL
-1245	NULL
and	NULL
-1066	NULL
.	NULL

Next	NULL
,	NULL
we	NULL
tested	NULL
this	NULL
region	NULL
for	NULL
enhancer	NULL
activity	NULL
by	NULL
inserting	NULL
the	NULL
missing	NULL
EBV-responsive	NULL
sequences	NULL
at	NULL
the	NULL
3	NULL
'	NULL
end	NULL
of	NULL
the	NULL
CAT	NULL
gene	NULL
in	NULL
the	NULL
inactive	NULL
deletion	NULL
plasmid	NULL
-1,066	NULL
CAT	NULL
.	NULL

As	NULL
shown	NULL
for	NULL
IB4	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
,	NULL
reintroducing	NULL
these	NULL
sequences	NULL
,	NULL
in	NULL
either	NULL
the	NULL
sense	NULL
or	NULL
antisense	NULL
orientation	NULL
,	NULL
fully	NULL
restored	NULL
transcriptional	NULL
activity	NULL
in	NULL
EBV	NULL
*	NULL
B-LCLs	NULL
to	NULL
levels	NULL
as	NULL
high	NULL
as	NULL
those	NULL
seen	NULL
with	NULL
deletion	NULL
construct	NULL
-1,245	NULL
CAT	NULL
.	NULL

This	NULL
result	NULL
demonstrates	NULL
that	NULL
the	NULL
EBV-responsive	NULL
element	NULL
(	NULL
s	NULL
)	NULL
behaves	NULL
in	NULL
an	NULL
ori-entation-	NULL
and	NULL
position-independent	NULL
manner	NULL
,	NULL
two	NULL
features	NULL
which	NULL
classically	NULL
define	NULL
an	NULL
enhancer	NULL
.	NULL

DNase	NULL
I	NULL
footprinting	NULL
of	NULL
the	NULL
EBV-responsive	NULL
element	NULL
.	NULL

We	NULL
performed	NULL
DNase	NULL
I	NULL
footprinting	NULL
analysis	NULL
with	NULL
EBV	NULL
'	NULL
B-LCL	NULL
and	NULL
EBV~	NULL
nuclear	NULL
protein	NULL
extracts	NULL
to	NULL
identify	NULL
nucleotide	NULL
sequences	NULL
that	NULL
could	NULL
mediate	NULL
EBV	NULL
responsiveness	NULL
of	NULL
the	NULL
CD48	NULL
gene	NULL
.	NULL

A	NULL
specific	NULL
footprint	NULL
was	NULL
obtained	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
lanes	NULL
2	NULL
to	NULL
5	NULL
)	NULL
when	NULL
a	NULL
labeled	NULL
DNA	NULL
probe	NULL
spanning	NULL
positions	NULL
-1181	NULL
to	NULL
-1053	NULL
was	NULL
incubated	NULL
with	NULL
nuclear	NULL
extracts	NULL
isolated	NULL
from	NULL
the	NULL
IB4	NULL
B-LCL	NULL
.	NULL

Neither	NULL
BJAB	NULL
nor	NULL
K562	NULL
nuclear	NULL
proteins	NULL
protected	NULL
this	NULL
probe	NULL
from	NULL
DNase	NULL
I	NULL
digestion	NULL
even	NULL
at	NULL
the	NULL
highest	NULL
concentration	NULL
of	NULL
extract	NULL
tested	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
lanes	NULL
6	NULL
to	NULL
11	NULL
)	NULL
.	NULL

The	NULL
same	NULL
footprint	NULL
was	NULL
obtained	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
JY	NULL
but	NULL
not	NULL
with	NULL
extracts	NULL
prepared	NULL
from	NULL
DG75	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
protected	NULL
nucleotide	NULL
sequence	NULL
,	NULL
5'-GGAAGGGGCITTCCCCA-3	NULL
'	NULL
,	NULL
was	NULL
localized	NULL
between	NULL
positions	NULL
-1149	NULL
and	NULL
-1133	NULL
.	NULL

EBV	NULL
*	NULL
nuclear	NULL
extracts	NULL
displayed	NULL
a	NULL
similar	NULL
footprint	NULL
on	NULL
the	NULL
comple-	NULL
mentary	NULL
strand	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

Comparison	NULL
with	NULL
known	NULL
binding	NULL
sites	NULL
for	NULL
nuclear	NULL
proteins	NULL
(	NULL
12	NULL
,	NULL
17	NULL
)	NULL
revealed	NULL
homology	NULL
of	NULL
the	NULL
core	NULL
protected	NULL
region	NULL
(	NULL
GGGGCTTTCC	NULL
)	NULL
to	NULL
a	NULL
consensus	NULL
binding	NULL
site	NULL
for	NULL
the	NULL
NF-	NULL
«	NULL
B/Rel	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
.	NULL

Mutational	NULL
analysis	NULL
of	NULL
the	NULL
putative	NULL
NF-KB	NULL
site	NULL
.	NULL

We	NULL
mutated	NULL
nucleotides	NULL
in	NULL
the	NULL
putative	NULL
NF-	NULL
«	NULL
B	NULL
motif	NULL
to	NULL
determine	NULL
whether	NULL
this	NULL
site	NULL
is	NULL
an	NULL
essential	NULL
component	NULL
of	NULL
the	NULL
EBV-responsive	NULL
element	NULL
.	NULL

Nucleotide	NULL
substitutions	NULL
that	NULL
would	NULL
ablate	NULL
an	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
as	NULL
judged	NULL
from	NULL
previously	NULL
published	NULL
analyses	NULL
(	NULL
3	NULL
,	NULL
17	NULL
)	NULL
were	NULL
chosen	NULL
.	NULL

Wild-type	NULL
and	NULL
mutated	NULL
DNA	NULL
fragments	NULL
spanning	NULL
positions	NULL
-1181	NULL
to	NULL
-1053	NULL
were	NULL
subjected	NULL
to	NULL
DNase	NULL
I	NULL
footprinting	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
from	NULL
the	NULL
EBV	NULL
*	NULL
B-LCL	NULL
IB4	NULL
.	NULL

Lane	NULL
6	NULL
to	NULL
9	NULL
of	NULL
Fig	NULL
.	NULL

5A	NULL
display	NULL
the	NULL
footprinting	NULL
pattern	NULL
for	NULL
mtl	NULL
,	NULL
a	NULL
probe	NULL
which	NULL
contains	NULL
nucleotide	NULL
substitutions	NULL
at	NULL
positions	NULL
2	NULL
and	NULL
9	NULL
of	NULL
the	NULL
NF-kB	NULL
consensus	NULL
site	NULL
.	NULL

A	NULL
protected	NULL
footprint	NULL
was	NULL
no	NULL
longer	NULL
evident	NULL
compared	NULL
with	NULL
the	NULL
wild-type	NULL
pattern	NULL
(	NULL
lanes	NULL
2	NULL
to	NULL
5	NULL
)	NULL
,	NULL
even	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
increasing	NULL
amounts	NULL
of	NULL
nuclear	NULL
extract	NULL
.	NULL

The	NULL
same	NULL
result	NULL
was	NULL
obtained	NULL
with	NULL
mt2	NULL
,	NULL
which	NULL
contains	NULL
four	NULL
nucleotide	NULL
substitutions	NULL
in	NULL
the	NULL
NF-kB	NULL
consensus	NULL
sequence	NULL
at	NULL
positions	NULL
1	NULL
,	NULL
4	NULL
,	NULL
8	NULL
,	NULL
and	NULL
10	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Mutated	NULL
-1.58	NULL
CAT	NULL
plasmids	NULL
were	NULL
generated	NULL
with	NULL
the	NULL
same	NULL
base	NULL
substitutions	NULL
described	NULL
above	NULL
for	NULL
mtl	NULL
and	NULL
mt2	NULL
.	NULL

The	NULL
relative	NULL
CAT	NULL
activities	NULL
of	NULL
the	NULL
wild-type	NULL
and	NULL
mutated	NULL
-1.58	NULL
CAT	NULL
plasmids	NULL
were	NULL
then	NULL
compared	NULL
to	NULL
determine	NULL
whether	NULL
the	NULL
putative	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
was	NULL
required	NULL
for	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
EBV-responsive	NULL
element	NULL
.	NULL

As	NULL
shown	NULL
for	NULL
1B4	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
,	NULL
the	NULL
mutated	NULL
-1.58	NULL
CAT	NULL
plasmids	NULL
were	NULL
not	NULL
able	NULL
to	NULL
stimulate	NULL
CAT	NULL
activity	NULL
following	NULL
transfection	NULL
into	NULL
the	NULL
EBV	NULL
*	NULL
B-LCLs	NULL
,	NULL
while	NULL
the	NULL
positive	NULL
control	NULL
pCMV/HTLV	NULL
CAT	NULL
and	NULL
wild-type	NULL
-1.58	NULL
CAT	NULL
VoL	NULL
.	NULL

69	NULL
,	NULL
1995	NULL
CD48	NULL
GENE	NULL
REGULATION	NULL
IN	NULL
EBV-IMMORTALIZED	NULL
B	NULL
CELLS	NULL
-	NULL
875	NULL
Hind	NULL
In	NULL
Nsp	NULL
I	NULL
-1,066	NULL
EX	NULL
1	NULL
INT	NULL
1	NULL
A.	NULL
si1	NULL
car	NULL
Q	NULL
[	NULL
car	NULL
)	NULL
$	NULL
CAT	NULL
~1.58	NULL
CAT	NULL
£	NULL
CAT	NULL
1,442	NULL
CAT	NULL
‘	NULL
CAT	NULL
-1,245	NULL
CAT	NULL
‘	NULL
f	NULL
CAT	NULL
1,066	NULL
CAT	NULL
‘	NULL
CAT	NULL
-999	NULL
CAT	NULL
“	NULL
CAT	NULL
896	NULL
cat	NULL
‘	NULL
B.	NULL
SL1	NULL
CAT	NULL
.	NULL

--	NULL
=ie	NULL
CAT	NULL
1.58	NULL
CAT	NULL
'	NULL
wie	NULL
[	NULL
cat	NULL
]	NULL
1,245	NULL
cat	NULL
$	NULL
CAT	NULL
-1,066	NULL
CAT	NULL
‘	NULL
¢	NULL
CAT	NULL
-1,066	NULL
CAT	NULL
.	NULL

CAT	NULL
-1,066	NULL
CAT	NULL
'	NULL
'	NULL
CM	NULL
1AC-CM	NULL
3AC-CM	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Fine	NULL
deletion	NULL
mapping	NULL
localizes	NULL
an	NULL
EBV-responsive	NULL
enhancer	NULL
element	NULL
.	NULL

The	NULL
structure	NULL
of	NULL
the	NULL
CD48	NULL
genomic	NULL
DNA	NULL
fragment	NULL
is	NULL
shown	NULL
.	NULL

EX	NULL
1	NULL
,	NULL
exon	NULL
1	NULL
;	NULL
INT	NULL
1	NULL
,	NULL
intron	NULL
1	NULL
.	NULL

(	NULL
A	NULL
)	NULL
A	NULL
finer	NULL
series	NULL
of	NULL
5'-deletion	NULL
constructs	NULL
were	NULL
generated	NULL
between	NULL
-1.58	NULL
CAT	NULL
and	NULL
-869	NULL
CAT	NULL
and	NULL
tested	NULL
for	NULL
transcriptional	NULL
activity	NULL
in	NULL
EBV	NULL
*	NULL
B-LCLs	NULL
(	NULL
results	NULL
shown	NULL
for	NULL
1B4	NULL
)	NULL
.	NULL

The	NULL
location	NULL
of	NULL
the	NULL
EBV-responsive	NULL
element	NULL
,	NULL
as	NULL
defined	NULL
by	NULL
fine	NULL
deletion	NULL
mapping	NULL
,	NULL
is	NULL
indicated	NULL
by	NULL
the	NULL
thick	NULL
bar	NULL
above	NULL
.	NULL

(	NULL
B	NULL
)	NULL
CD48	NULL
enhancer	NULL
constructs	NULL
were	NULL
derived	NULL
by	NULL
subcloning	NULL
the	NULL
EBV-responsive	NULL
element	NULL
(	NULL
bold	NULL
arrows	NULL
)	NULL
into	NULL
plasmid	NULL
-1,066	NULL
CAT	NULL
at	NULL
the	NULL
3	NULL
'	NULL
end	NULL
of	NULL
the	NULL
bacterial	NULL
CAT	NULL
reporter	NULL
gene	NULL
in	NULL
either	NULL
the	NULL
sense	NULL
(	NULL
-	NULL
>	NULL
)	NULL
or	NULL
antisense	NULL
(	NULL
«	NULL
-	NULL
)	NULL
orientation	NULL
.	NULL

-1.58	NULL
CAT	NULL
and	NULL
the	NULL
CD48	NULL
enhancer	NULL
constructs	NULL
were	NULL
tested	NULL
for	NULL
transcriptional	NULL
activity	NULL
in	NULL
EBV	NULL
*	NULL
B-LCLs	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

1	NULL
(	NULL
results	NULL
shown	NULL
for	NULL
1B4	NULL
)	NULL
.	NULL

plasmids	NULL
demonstrated	NULL
high	NULL
levels	NULL
of	NULL
activity	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
following	NULL
transfection	NULL
of	NULL
the	NULL
mutated	NULL
plasmids	NULL
into	NULL
JY	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
mutagenesis	NULL
of	NULL
the	NULL
putative	NULL
NF-kB	NULL
site	NULL
resulted	NULL
in	NULL
concomitant	NULL
loss	NULL
of	NULL
the	NULL
specific	NULL
DNase	NULL
I	NULL
footprint	NULL
and	NULL
detectable	NULL
enhancer	NULL
activity	NULL
.	NULL

We	NULL
conclude	NULL
,	NULL
therefore	NULL
,	NULL
that	NULL
the	NULL
putative	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
is	NULL
an	NULL
essential	NULL
component	NULL
of	NULL
the	NULL
EBV	NULL
-responsive	NULL
element	NULL
.	NULL

Identification	NULL
of	NULL
protein	NULL
complexes	NULL
binding	NULL
to	NULL
the	NULL
EBV-responsive	NULL
element	NULL
.	NULL

EMSAs	NULL
were	NULL
performed	NULL
to	NULL
identify	NULL
the	NULL
nuclear	NULL
protein	NULL
complexes	NULL
that	NULL
bound	NULL
to	NULL
the	NULL
EBV-responsive	NULL
element	NULL
.	NULL

A	NULL
DNA	NULL
mobility	NULL
shift	NULL
pattern	NULL
was	NULL
observed	NULL
with	NULL
EBV	NULL
*	NULL
B-LCL	NULL
nuclear	NULL
extracts	NULL
incubated	NULL
with	NULL
a	NULL
labeled	NULL
DNA	NULL
probe	NULL
spanning	NULL
positions	NULL
-1181	NULL
to	NULL
-1053	NULL
,	NULL
which	NULL
includes	NULL
the	NULL
EBV-responsive	NULL
region	NULL
.	NULL

A	NULL
diffuse	NULL
set	NULL
of	NULL
bands	NULL
(	NULL
upper	NULL
arrow	NULL
876	NULL
KLAMAN	NULL
AND	NULL
THORLEY-LAWSON	NULL
J.	NULL
Hind	NULL
III	NULL
Nsp	NULL
I	NULL
-1,181	NULL
-1,053	NULL
EX	NULL
1	NULL
1B4	NULL
K562	NULL
-	NULL
BJAB	NULL
1B4	NULL
=-	NULL
1012515	NULL
10	NULL
12.5	NULL
15	NULL
10	NULL
12.5	NULL
15	NULL
ug	NULL
Extract	NULL
-	NULL
-	NULL
5	NULL
7.5	NULL
10	NULL
12.5	NULL
15	NULL
ug	NULL
Protein	NULL
«	NULL
»	NULL
I	NULL
m	NULL
«	NULL
n	NULL
«	NULL
w	NULL
-	NULL
@	NULL
h	NULL
_	NULL
t	NULL
«	NULL
»	NULL
%	NULL
£	NULL
&	NULL
4	NULL
*	NULL
B	NULL
S	NULL
€	NULL
\	NULL
®	NULL
:	NULL
o	NULL
:	NULL
ie	NULL
08	NULL
n	NULL
®	NULL
@	NULL
#	NULL
#	NULL
8	NULL
a	NULL
-	NULL
#	NULL
z	NULL
é	NULL
#	NULL
%	NULL
&	NULL
-	NULL
#	NULL
1	NULL
2	NULL
B	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
11	NULL
5	NULL
'	NULL
31	NULL
L	NULL
40044	NULL
>	NULL
000044409990	NULL
>	NULL
$	NULL
u	NULL
@	NULL
&	NULL
-	NULL
e	NULL
@	NULL
@	NULL
+	NULL
bel	NULL
10	NULL
0o4	NULL
<	NULL
00000	NULL
»	NULL
}	NULL
»	NULL
}	NULL
»	NULL
}	NULL
0	NULL
0	NULL
0	NULL
O	NULL
7	NULL
,	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
--	NULL
GGAAGGGGCTTTCCCCATTGCT	NULL
3	NULL
``	NULL
TTCCTTCCCCGAAAGGCGGT	NULL
--	NULL
--	NULL
--	NULL
5	NULL
``	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Identification	NULL
of	NULL
an	NULL
NF-xB	NULL
DNA	NULL
binding	NULL
motif	NULL
within	NULL
the	NULL
EBV-responsive	NULL
element	NULL
by	NULL
DNase	NULL
I	NULL
protection	NULL
assay	NULL
.	NULL

The	NULL
structure	NULL
of	NULL
the	NULL
CD48	NULL
genomic	NULL
DNA	NULL
fragment	NULL
is	NULL
shown	NULL
;	NULL
the	NULL
thick	NULL
bar	NULL
indicates	NULL
the	NULL
boundaries	NULL
of	NULL
the	NULL
DNase	NULL
I	NULL
footprinting	NULL
probes	NULL
which	NULL
were	NULL
incubated	NULL
with	NULL
crude	NULL
nuclear	NULL
protein	NULL
extracts	NULL
from	NULL
EBV	NULL
*	NULL
or	NULL
EBV~	NULL
cell	NULL
lines	NULL
.	NULL

Ex	NULL
1	NULL
,	NULL
exon	NULL
1	NULL
.	NULL

The	NULL
number	NULL
above	NULL
each	NULL
lane	NULL
indicates	NULL
the	NULL
amount	NULL
of	NULL
protein	NULL
extract	NULL
added	NULL
to	NULL
the	NULL
binding	NULL
reaction	NULL
(	NULL
in	NULL
micrograms	NULL
)	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Demonstration	NULL
of	NULL
a	NULL
specific	NULL
footprint	NULL
with	NULL
EBV	NULL
*	NULL
but	NULL
not	NULL
EBV~	NULL
nuclear	NULL
extracts	NULL
.	NULL

The	NULL
protected	NULL
region	NULL
was	NULL
determined	NULL
by	NULL
reference	NULL
to	NULL
a	NULL
G+A	NULL
Maxam-Gilbert	NULL
ladder	NULL
,	NULL
resolved	NULL
in	NULL
parallel	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
and	NULL
is	NULL
bracketed	NULL
at	NULL
the	NULL
right	NULL
,	NULL
with	NULL
the	NULL
5	NULL
'	NULL
and	NULL
3	NULL
'	NULL
orientation	NULL
noted	NULL
.	NULL

(	NULL
B	NULL
)	NULL
EBV	NULL
*	NULL
IB4-LCL	NULL
nuclear	NULL
extracts	NULL
protect	NULL
the	NULL
identical	NULL
sequence	NULL
(	NULL
bracketed	NULL
at	NULL
the	NULL
right	NULL
)	NULL
on	NULL
the	NULL
complementary	NULL
strand	NULL
.	NULL

Protected	NULL
regions	NULL
identified	NULL
in	NULL
panels	NULL
A	NULL
and	NULL
B	NULL
are	NULL
aligned	NULL
below	NULL
,	NULL
with	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
shown	NULL
in	NULL
boldface	NULL
.	NULL

head	NULL
)	NULL
and	NULL
two	NULL
tightly	NULL
resolved	NULL
bands	NULL
(	NULL
middle	NULL
and	NULL
lower	NULL
arrow-heads	NULL
)	NULL
were	NULL
detected	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

The	NULL
middle	NULL
band	NULL
was	NULL
not	NULL
detected	NULL
with	NULL
EBV	NULL
~	NULL
nuclear	NULL
extracts	NULL
(	NULL
lanes	NULL
3	NULL
to	NULL
5	NULL
)	NULL
,	NULL
even	NULL
when	NULL
10-fold	NULL
more	NULL
nuclear	NULL
extract	NULL
was	NULL
added	NULL
to	NULL
the	NULL
EMSA	NULL
.	NULL

The	NULL
protein-DNA	NULL
complexes	NULL
(	NULL
middle	NULL
and	NULL
lower	NULL
ar-rowheads	NULL
)	NULL
were	NULL
specific	NULL
since	NULL
they	NULL
were	NULL
efficiently	NULL
competed	NULL
for	NULL
with	NULL
a	NULL
25-	NULL
to	NULL
200-fold	NULL
molar	NULL
excess	NULL
of	NULL
unlabeled	NULL
target	NULL
DNA	NULL
(	NULL
lanes	NULL
7	NULL
to	NULL
10	NULL
)	NULL
but	NULL
not	NULL
with	NULL
unrelated	NULL
binding	NULL
sites	NULL
(	NULL
EBNA-1	NULL
;	NULL
lanes	NULL
11	NULL
to	NULL
14	NULL
;	NULL
Oct-1	NULL
,	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

If	NULL
the	NULL
putative	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
was	NULL
mutated	NULL
,	NULL
the	NULL
specific	NULL
protein-DNA	NULL
complexes	NULL
were	NULL
no	NULL
longer	NULL
detected	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
;	NULL
compare	NULL
lane	NULL
2	NULL
with	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
nor	NULL
could	NULL
unlabeled	NULL
,	NULL
mutated	NULL
DNA	NULL
compete	NULL
with	NULL
the	NULL
wild-type	NULL
probe	NULL
for	NULL
binding	NULL
of	NULL
the	NULL
complexes	NULL
when	NULL
added	NULL
at	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

A	NULL
second	NULL
band	NULL
(	NULL
lower	NULL
ar-rowhead	NULL
)	NULL
was	NULL
also	NULL
detected	NULL
with	NULL
EBV	NULL
*	NULL
B-LCLs	NULL
nuclear	NULL
extracts	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
;	NULL
Fig	NULL
.	NULL

7	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

This	NULL
lower	NULL
band	NULL
could	NULL
not	NULL
be	NULL
considered	NULL
specific	NULL
since	NULL
(	NULL
i	NULL
)	NULL
it	NULL
was	NULL
also	NULL
detected	NULL
with	NULL
EBV~	NULL
nuclear	NULL
extracts	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
lanes	NULL
3	NULL
to	NULL
5	NULL
;	NULL
Fig	NULL
.	NULL

7A	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
and	NULL
(	NULL
ii	NULL
)	NULL
it	NULL
was	NULL
inefficiently	NULL
competed	NULL
for	NULL
with	NULL
a	NULL
25-	NULL
to	NULL
200-fold	NULL
molar	NULL
excess	NULL
of	NULL
the	NULL
corresponding	NULL
unlabeled	NULL
DNA	NULL
fragment	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
lanes	NULL
7	NULL
to	NULL
10	NULL
)	NULL
.	NULL

We	NULL
conclude	NULL
,	NULL
therefore	NULL
,	NULL
that	NULL
a	NULL
specific	NULL
nuclear	NULL
protein	NULL
complex	NULL
,	NULL
found	NULL
in	NULL
EBV	NULL
B-LCLs	NULL
,	NULL
binds	NULL
to	NULL
the	NULL
EBV-responsive	NULL
element	NULL
and	NULL
that	NULL
the	NULL
putative	NULL
NF-KB	NULL
site	NULL
is	NULL
essential	NULL
for	NULL
binding	NULL
of	NULL
the	NULL
complex	NULL
.	NULL

Competitive	NULL
EMSA	NULL
analysis	NULL
.	NULL

Competitive	NULL
EMSA	NULL
analysis	NULL
was	NULL
performed	NULL
with	NULL
a	NULL
known	NULL
NF-	NULL
«	NULL
B	NULL
DNA	NULL
binding	NULL
motif	NULL
as	NULL
an	NULL
initial	NULL
test	NULL
of	NULL
whether	NULL
factors	NULL
are	NULL
components	NULL
of	NULL
the	NULL
nuclear	NULL
protein-DNA	NULL
complexes	NULL
detected	NULL
with	NULL
EBV	NULL
'*	NULL
B-LCLs	NULL
.	NULL

As	NULL
shown	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
,	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
)	NULL
,	NULL
competition	NULL
with	NULL
a	NULL
50-	NULL
or	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
an	NULL
unlabeled	NULL
34-bp	NULL
oligonucle-otide	NULL
,	NULL
containing	NULL
the	NULL
human	NULL
Igx	NULL
light-chain	NULL
NF-	NULL
«	NULL
B	NULL
consensus	NULL
sequence	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
)	NULL
,	NULL
prevented	NULL
formation	NULL
of	NULL
both	NULL
the	NULL
Vou	NULL
.	NULL

69	NULL
,	NULL
1995	NULL
Hind	NULL
lil	NULL
Nsp	NULL
I	NULL
T*	NULL
``	NULL
~1,181	NULL
-1,053	NULL
EX	NULL
1	NULL
L	NULL
]	NULL
A	NULL
.	NULL

Probe	NULL
W.T	NULL
.	NULL

mt1	NULL
1B4	NULL
nuclear	NULL
extract	NULL
(	NULL
ug	NULL
protein	NULL
)	NULL
20	NULL
15	NULL
10	NULL
-	NULL
20	NULL
15	NULL
10	NULL
<	NULL
<	NULL
G	NULL
[	NULL
m_	NULL
[	NULL
mms	NULL
g	NULL
1	NULL
?	NULL
``	NULL

m	NULL
a	NULL
a	NULL
a	NULL
0	NULL
a	NULL
#	NULL
#	NULL
aon	NULL
#	NULL
py	NULL
*~	NULL
#	NULL
m	NULL
a	NULL
#	NULL
#	NULL
a	NULL
&	NULL
|	NULL
-	NULL
U	NULL
_	NULL
|	NULL
G	NULL
me	NULL
#	NULL
§	NULL
&	NULL
i	NULL
a	NULL
7	NULL
C	NULL
c	NULL
g	NULL
:	NULL
x	NULL
s	NULL
2	NULL
&	NULL
&	NULL
§	NULL
&	NULL
e	NULL
i	NULL
s	NULL
a	NULL
S	NULL
i	NULL
Ae	NULL
c	NULL
*	NULL
5	NULL
a	NULL
$	NULL
#	NULL
C	NULL
r	NULL
5B	NULL
f	NULL
f	NULL
f	NULL
|	NULL
:	NULL
®	NULL
T	NULL
hs	NULL
=o	NULL
:	NULL
%	NULL
3	NULL
2	NULL
|	NULL
``	NULL
r	NULL
*=	NULL
#	NULL
fof	NULL
f	NULL
°	NULL
z	NULL
T	NULL
go	NULL
fff	NULL
:	NULL
a	NULL
=	NULL
=	NULL
os	NULL
se	NULL
ir	NULL
t	NULL
$	NULL
f	NULL
43	NULL
#	NULL
z	NULL
go	NULL
#	NULL
ogo	NULL
:	NULL
*	NULL
§	NULL
GG	NULL
p	NULL
:	NULL
f	NULL
'	NULL
5	NULL
&	NULL
|	NULL
i	NULL
g	NULL
4	NULL
=	NULL
s	NULL
%	NULL
#	NULL
#	NULL
P	NULL
lno.d	NULL
w	NULL
oe	NULL
%	NULL
£	NULL
bed	NULL
i	NULL
s	NULL
*	NULL
3	NULL
y	NULL
g	NULL
.	NULL

#	NULL
Wa	NULL
-	NULL
I	NULL
ii	NULL
~	NULL
g	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
B	NULL
.	NULL

%	NULL
Conversion	NULL
SL1	NULL
CAT	NULL
0	NULL
0.4	NULL
ceccermrce	NULL
_-	NULL
1.58	NULL
H/N	NULL
CD48	NULL
CAT	NULL
0	NULL
``	NULL
es	NULL
cceecrrrec	NULL
mtl	NULL
0	NULL
0.3	NULL
mesrorrgeg	NULL
mi2	NULL
©	NULL
0.3	NULL
CMV/HTLV	NULL
cat	NULL
©	NULL
%	NULL
Q	NULL
04	NULL
C	NULL
Ms	NULL
,	NULL
%	NULL
tr	NULL
``	NULL
o	NULL
40-04	NULL
,	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

Mutational	NULL
analysis	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
within	NULL
the	NULL
EBV-responsive	NULL
element	NULL
.	NULL

The	NULL
structure	NULL
of	NULL
the	NULL
CD48	NULL
genomic	NULL
DNA	NULL
fragment	NULL
is	NULL
shown	NULL
;	NULL
the	NULL
thick	NULL
bar	NULL
indicates	NULL
the	NULL
boundaries	NULL
of	NULL
the	NULL
DNase	NULL
I	NULL
footprinting	NULL
probe	NULL
.	NULL

Ex	NULL
1	NULL
,	NULL
exon	NULL
1	NULL
.	NULL

(	NULL
A	NULL
)	NULL
DNase	NULL
I	NULL
footprinting	NULL
analysis	NULL
of	NULL
CD48	NULL
sequences	NULL
containing	NULL
either	NULL
a	NULL
wild-type	NULL
(	NULL
W.T	NULL
.	NULL

;	NULL
lanes	NULL
2	NULL
to	NULL
5	NULL
)	NULL
or	NULL
mutated	NULL
(	NULL
mtl	NULL
;	NULL
lanes	NULL
6	NULL
to	NULL
9	NULL
)	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
within	NULL
the	NULL
EBV-responsive	NULL
element	NULL
(	NULL
results	NULL
displayed	NULL
for	NULL
1B4	NULL
nuclear	NULL
extracts	NULL
)	NULL
.	NULL

The	NULL
protected	NULL
region	NULL
was	NULL
determined	NULL
by	NULL
reference	NULL
to	NULL
a	NULL
G+A	NULL
Maxam-Gilbert	NULL
ladder	NULL
,	NULL
resolved	NULL
in	NULL
parallel	NULL
(	NULL
lanes	NULL
1	NULL
[	NULL
wild-type	NULL
G+A	NULL
]	NULL
and	NULL
10	NULL
[	NULL
mutant	NULL
G+AJ	NULL
)	NULL
.	NULL

The	NULL
protected	NULL
region	NULL
is	NULL
indicated	NULL
at	NULL
the	NULL
left	NULL
for	NULL
the	NULL
wild-type	NULL
sequence	NULL
,	NULL
while	NULL
the	NULL
unprotected	NULL
mutated	NULL
sequence	NULL
is	NULL
bracketed	NULL
at	NULL
the	NULL
right	NULL
.	NULL

Mutated	NULL
nucleotides	NULL
are	NULL
underlined	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Transcriptional	NULL
activity	NULL
in	NULL
1B4	NULL
of	NULL
-1.58	NULL
CAT	NULL
reporter	NULL
gene	NULL
constructs	NULL
containing	NULL
either	NULL
a	NULL
wild-type	NULL
or	NULL
mutated	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
within	NULL
the	NULL
EBV-responsive	NULL
element	NULL
.	NULL

The	NULL
sequences	NULL
of	NULL
the	NULL
wild-type	NULL
and	NULL
mutated	NULL
(	NULL
mtl	NULL
and	NULL
mt2	NULL
)	NULL
NF-	NULL
«	NULL
B	NULL
sites	NULL
are	NULL
indicated	NULL
,	NULL
with	NULL
mutated	NULL
nucleotides	NULL
underlined	NULL
.	NULL

middle	NULL
and	NULL
upper	NULL
broad	NULL
complex	NULL
of	NULL
bands	NULL
.	NULL

Again	NULL
,	NULL
the	NULL
lower	NULL
nonspecific	NULL
band	NULL
was	NULL
not	NULL
affected	NULL
.	NULL

Unlabeled	NULL
probe	NULL
,	NULL
used	NULL
as	NULL
a	NULL
specific	NULL
competitor	NULL
DNA	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
3	NULL
)	NULL
,	NULL
or	NULL
an	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
mouse	NULL
Igk	NULL
light-chain	NULL
NF-kB	NULL
consensus	NULL
site	NULL
CD48	NULL
GENE	NULL
REGULATION	NULL
IN	NULL
EBV-IMMORTALIZED	NULL
B	NULL
CELLS	NULL
877	NULL
Hind	NULL
11	NULL
-	NULL
Nap	NULL
I	NULL
1,181	NULL
1,053	NULL
EX	NULL
1	NULL
INT	NULL
1	NULL
1B4	NULL
Specific	NULL
Non-Specific	NULL
~	NULL
25	NULL
50	NULL
100	NULL
200	NULL
25	NULL
50	NULL
100	NULL
200	NULL
Fold	NULL
Competitor	NULL
184	NULL
JY	NULL
K562	NULL
BJAB	NULL
Jurkat	NULL
M	NULL
_L	NULL
,	NULL
Fw	NULL
B-	NULL
»	NULL
%	NULL
&	NULL
o	NULL
000	NULL
a	NULL
a	NULL
a	NULL
a	NULL
1	NULL
2003	NULL
405	NULL
60	NULL
7	NULL
O8	NULL
90	NULL
10	NULL
11	NULL
G2	NULL
13	NULL
14	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

Specific	NULL
protein-DNA	NULL
interactions	NULL
within	NULL
the	NULL
EBV-responsive	NULL
sequences	NULL
detected	NULL
by	NULL
EMSA	NULL
.	NULL

The	NULL
structure	NULL
of	NULL
the	NULL
CD48	NULL
genomic	NULL
DNA	NULL
fragment	NULL
is	NULL
shown	NULL
at	NULL
the	NULL
top	NULL
;	NULL
the	NULL
thick	NULL
bar	NULL
indicates	NULL
the	NULL
boundaries	NULL
of	NULL
the	NULL
EMSA	NULL
probe	NULL
.	NULL

Ex	NULL
1	NULL
,	NULL
exon	NULL
1	NULL
;	NULL
INT	NULL
1	NULL
,	NULL
intron	NULL
1	NULL
.	NULL

This	NULL
DNA	NULL
probe	NULL
was	NULL
incubated	NULL
with	NULL
crude	NULL
nuclear	NULL
proteins	NULL
from	NULL
EBV	NULL
*	NULL
or	NULL
EBV~	NULL
cell	NULL
lines	NULL
and	NULL
subjected	NULL
to	NULL
EMSA	NULL
(	NULL
lane	NULL
6	NULL
,	NULL
no	NULL
extract	NULL
control	NULL
)	NULL
.	NULL

Upper	NULL
and	NULL
middle	NULL
arrowheads	NULL
denote	NULL
EBV-specific	NULL
complexes	NULL
.	NULL

The	NULL
lower	NULL
arrowhead	NULL
denotes	NULL
a	NULL
nonspecific	NULL
complex	NULL
shifted	NULL
with	NULL
all	NULL
extracts	NULL
.	NULL

For	NULL
binding	NULL
reactions	NULL
which	NULL
include	NULL
competitors	NULL
(	NULL
lanes	NULL
7	NULL
to	NULL
14	NULL
)	NULL
,	NULL
the	NULL
fold	NULL
molar	NULL
excess	NULL
is	NULL
shown	NULL
above	NULL
each	NULL
lane	NULL
.	NULL

In	NULL
this	NULL
experiment	NULL
,	NULL
unlabeled	NULL
probe	NULL
was	NULL
the	NULL
specific	NULL
competitor	NULL
and	NULL
the	NULL
EBNA-1	NULL
binding	NULL
site	NULL
was	NULL
the	NULL
nonspecific	NULL
competitor	NULL
.	NULL

(	NULL
not	NULL
shown	NULL
)	NULL
also	NULL
competed	NULL
efficiently	NULL
for	NULL
binding	NULL
to	NULL
the	NULL
putative	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
,	NULL
while	NULL
an	NULL
oligonucleotide	NULL
with	NULL
a	NULL
mutated	NULL
Igk	NULL
NF-KB	NULL
site	NULL
failed	NULL
to	NULL
compete	NULL
for	NULL
binding	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

These	NULL
findings	NULL
suggest	NULL
that	NULL
NF-	NULL
«	NULL
B-related	NULL
proteins	NULL
bind	NULL
to	NULL
the	NULL
EBV-responsive	NULL
element	NULL
.	NULL

NF-B1	NULL
(	NULL
p50	NULL
)	NULL
is	NULL
a	NULL
component	NULL
of	NULL
the	NULL
middle	NULL
nuclear	NULL
protein	NULL
complex	NULL
.	NULL

Supershifting	NULL
antisera	NULL
,	NULL
raised	NULL
against	NULL
several	NULL
NF-	NULL
«	NULL
xB/	NULL
Rel	NULL
family	NULL
proteins	NULL
,	NULL
were	NULL
included	NULL
in	NULL
the	NULL
EMSA	NULL
binding	NULL
reaction	NULL
to	NULL
identify	NULL
which	NULL
protein	NULL
subunits	NULL
are	NULL
present	NULL
in	NULL
the	NULL
specific	NULL
complexes	NULL
.	NULL

We	NULL
were	NULL
able	NULL
to	NULL
directly	NULL
demonstrate	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
NF-kB1	NULL
(	NULL
p50	NULL
)	NULL
protein	NULL
subunit	NULL
in	NULL
these	NULL
complexes	NULL
with	NULL
two	NULL
independently	NULL
raised	NULL
antisera	NULL
(	NULL
Fig	NULL
.	NULL

7C	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
3	NULL
)	NULL
.	NULL

Compared	NULL
with	NULL
preimmune	NULL
sera	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
the	NULL
immune	NULL
antisera	NULL
clearly	NULL
supershifted	NULL
the	NULL
entire	NULL
middle	NULL
complex	NULL
and	NULL
altered	NULL
the	NULL
mobility	NULL
of	NULL
the	NULL
diffuse	NULL
upper	NULL
bands	NULL
as	NULL
well	NULL
.	NULL

Therefore	NULL
,	NULL
one	NULL
of	NULL
the	NULL
specific	NULL
nuclear	NULL
proteins	NULL
that	NULL
binds	NULL
to	NULL
the	NULL
EBV-responsive	NULL
element	NULL
is	NULL
(	NULL
p50	NULL
)	NULL
.	NULL

Antisera	NULL
directed	NULL
against	NULL
epitopes	NULL
of	NULL
the	NULL
RelA	NULL
(	NULL
p65	NULL
)	NULL
or	NULL
c-rel	NULL
family	NULL
members	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
apparent	NULL
mobility	NULL
of	NULL
the	NULL
middle	NULL
complex	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
it	NULL
may	NULL
be	NULL
a	NULL
p50	NULL
homodimer	NULL
.	NULL

However	NULL
,	NULL
we	NULL
do	NULL
have	NULL
preliminary	NULL
evidence	NULL
to	NULL
suggest	NULL
that	NULL
components	NULL
of	NULL
the	NULL
upper	NULL
diffuse	NULL
bands	NULL
are	NULL
shifted	NULL
with	NULL
these	NULL
antisera	NULL
.	NULL

Function	NULL
of	NULL
the	NULL
EBV-inducible	NULL
element	NULL
in	NULL
EBV	NULL
-	NULL
B-cell	NULL
tumor	NULL
lines	NULL
before	NULL
and	NULL
after	NULL
conversion	NULL
with	NULL
EBV	NULL
.	NULL

The	NULL
CD48	NULL
gene	NULL
is	NULL
active	NULL
in	NULL
lymphoid	NULL
lines	NULL
,	NULL
irrespective	NULL
of	NULL
their	NULL
EBV	NULL
status	NULL
.	NULL

The	NULL
deletion	NULL
analysis	NULL
demonstrated	NULL
that	NULL
this	NULL
reflected	NULL
the	NULL
action	NULL
of	NULL
different	NULL
positive	NULL
regulatory	NULL
elements	NULL
,	NULL
an	NULL
EBV-inducible	NULL
element	NULL
for	NULL
EBV	NULL
*	NULL
B-LCLs	NULL
and	NULL
an	NULL
unmapped	NULL
element	NULL
for	NULL
the	NULL
EBV	NULL
~	NULL
lymphoid	NULL
tumor	NULL
lines	NULL
.	NULL

It	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
infection	NULL
of	NULL
EBV	NULL
~	NULL
B-lymphoid	NULL
tumor	NULL
lines	NULL
causes	NULL
them	NULL
to	NULL
become	NULL
more	NULL
lymphoblastoid	NULL
in	NULL
phenotype	NULL
(	NULL
7	NULL
,	NULL
9	NULL
,	NULL
42	NULL
)	NULL
.	NULL

We	NULL
wished	NULL
to	NULL
test	NULL
if	NULL
infection	NULL
of	NULL
these	NULL
cells	NULL
could	NULL
drive	NULL
them	NULL
far	NULL
878	NULL
KLAMAN	NULL
AND	NULL
THORLEY-LAWSON	NULL
J.	NULL
ViroL	NULL
.	NULL

A	NULL
JY	NULL
_	NULL
BJAB	NULL
B	NULL
Fo	NULL
o	NULL
93	NULL
C_	NULL
o	NULL
&	NULL
>	NULL
&	NULL
D	NULL
Competitor	NULL
649	NULL
“	NULL
&	NULL
£	NULL
Antiserum	NULL
opS50	NULL
PJ	NULL
.	NULL

op5	NULL
&	NULL
£	NULL
¢	NULL
&	NULL
Fold	NULL
-	NULL
50	NULL
100	NULL
50	NULL
100	NULL
100	NULL
1	NULL
2	NULL
3	NULL
4	NULL
-	NULL
us	NULL
3	NULL
am	NULL
FIG	NULL
.	NULL

7	NULL
.	NULL

EMSA	NULL
analysis	NULL
of	NULL
the	NULL
specific	NULL
complexes	NULL
binding	NULL
to	NULL
the	NULL
EBV-responsive	NULL
element	NULL
.	NULL

(	NULL
A	NULL
)	NULL
EMSA	NULL
comparing	NULL
binding	NULL
profiles	NULL
of	NULL
DNA	NULL
probes	NULL
containing	NULL
either	NULL
a	NULL
wild-type	NULL
or	NULL
mutated	NULL
NF-xB	NULL
site	NULL
within	NULL
the	NULL
EBV-responsive	NULL
element	NULL
.	NULL

End-labeled	NULL
DNA	NULL
probes	NULL
were	NULL
incubated	NULL
with	NULL
crude	NULL
nuclear	NULL
proteins	NULL
from	NULL
the	NULL
EBV	NULL
*	NULL
B-LCL	NULL
JY	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
or	NULL
the	NULL
EBV~	NULL
BJAB	NULL
cell	NULL
line	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
and	NULL
subjected	NULL
to	NULL
native	NULL
gel	NULL
electrophoresis	NULL
.	NULL

The	NULL
DNA	NULL
probe	NULL
used	NULL
in	NULL
the	NULL
binding	NULL
reaction	NULL
,	NULL
either	NULL
wild	NULL
type	NULL
(	NULL
W.T	NULL
.	NULL
)	NULL

or	NULL
mt1	NULL
,	NULL
is	NULL
indicated	NULL
above	NULL
each	NULL
lane	NULL
.	NULL

Upper	NULL
and	NULL
middle	NULL
arrowheads	NULL
denote	NULL
EBV-specific	NULL
complexes	NULL
formed	NULL
with	NULL
the	NULL
wild-type	NULL
EMSA	NULL
probe	NULL
but	NULL
not	NULL
with	NULL
the	NULL
mutated	NULL
probe	NULL
.	NULL

The	NULL
lower	NULL
arrowhead	NULL
denotes	NULL
a	NULL
nonspecific	NULL
complex	NULL
shifted	NULL
with	NULL
all	NULL
extracts	NULL
.	NULL

(	NULL
B	NULL
)	NULL
NF-	NULL
«	NULL
B	NULL
oligonucleotide	NULL
competition	NULL
experiment	NULL
.	NULL

An	NULL
end-labeled	NULL
DNA	NULL
probe	NULL
,	NULL
spanning	NULL
the	NULL
EBV-responsive	NULL
element	NULL
(	NULL
-1.181	NULL
to	NULL
-1053	NULL
)	NULL
,	NULL
was	NULL
incubated	NULL
with	NULL
EBV	NULL
*	NULL
B-LCL	NULL
nuclear	NULL
extracts	NULL
(	NULL
shown	NULL
for	NULL
1B4	NULL
;	NULL
lanes	NULL
1	NULL
to	NULL
6	NULL
)	NULL
.	NULL

Upper	NULL
and	NULL
middle	NULL
arrowheads	NULL
denote	NULL
EBV-specific	NULL
complexes	NULL
which	NULL
are	NULL
competed	NULL
for	NULL
when	NULL
unlabeled	NULL
probe	NULL
DNA	NULL
(	NULL
specific	NULL
;	NULL
lanes	NULL
2	NULL
and	NULL
3	NULL
)	NULL
or	NULL
a	NULL
34-bp	NULL
oligonucleotide	NULL
containing	NULL
a	NULL
wild-type	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
site	NULL
(	NULL
human	NULL
Ig	NULL
«	NULL
light-chain	NULL
intronic	NULL
«	NULL
B	NULL
site	NULL
[	NULL
big	NULL
«	NULL
kB	NULL
]	NULL
;	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
)	NULL
is	NULL
added	NULL
to	NULL
the	NULL
reaction	NULL
but	NULL
not	NULL
when	NULL
an	NULL
oligonucleotide	NULL
containing	NULL
a	NULL
mutated	NULL
higkB	NULL
site	NULL
is	NULL
added	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

No	NULL
competitor	NULL
was	NULL
added	NULL
to	NULL
lane	NULL
1	NULL
.	NULL

The	NULL
lower	NULL
arrowhead	NULL
denotes	NULL
a	NULL
nonspecific	NULL
complex	NULL
shifted	NULL
with	NULL
all	NULL
extracts	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Supershifting	NULL
analysis	NULL
of	NULL
the	NULL
protein-DNA	NULL
complexes	NULL
bound	NULL
to	NULL
the	NULL
EBV-responsive	NULL
element	NULL
.	NULL

Independently	NULL
raised	NULL
supershifting	NULL
antisera	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
3	NULL
)	NULL
,	NULL
directed	NULL
against	NULL
different	NULL
regions	NULL
of	NULL
the	NULL
N	NULL
terminus	NULL
of	NULL
NF-	NULL
«	NULL
B1	NULL
(	NULL
p50	NULL
)	NULL
,	NULL
were	NULL
added	NULL
to	NULL
the	NULL
EMSA	NULL
binding	NULL
reaction	NULL
mixtures	NULL
containing	NULL
[	NULL
B4	NULL
nuclear	NULL
extracts	NULL
(	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

Upper	NULL
and	NULL
middle	NULL
filled	NULL
arrowheads	NULL
denote	NULL
complexes	NULL
which	NULL
are	NULL
supershifted	NULL
with	NULL
specific	NULL
antisera	NULL
but	NULL
not	NULL
with	NULL
preimmune	NULL
sera	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

The	NULL
open	NULL
arrowhead	NULL
denotes	NULL
the	NULL
position	NULL
of	NULL
supershifted	NULL
complexes	NULL
.	NULL

P.L	NULL
,	NULL
preimmune	NULL
sera	NULL
.	NULL

enough	NULL
toward	NULL
the	NULL
lymphoblastoid	NULL
phenotype	NULL
to	NULL
allow	NULL
the	NULL
EBV	NULL
-responsive	NULL
element	NULL
to	NULL
become	NULL
active	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

8A	NULL
,	NULL
-1.58	NULL
CAT	NULL
showed	NULL
equivalent	NULL
and	NULL
low	NULL
activities	NULL
in	NULL
BL41	NULL
and	NULL
BJAB	NULL
whether	NULL
they	NULL
were	NULL
uninfected	NULL
or	NULL
infected	NULL
with	NULL
the	NULL
laboratory	NULL
strain	NULL
B95-8	NULL
,	NULL
used	NULL
to	NULL
make	NULL
the	NULL
EBV	NULL
*	NULL
B-LCLs	NULL
in	NULL
Table	NULL
1	NULL
.	NULL

Furthermore	NULL
,	NULL
no	NULL
difference	NULL
in	NULL
activity	NULL
was	NULL
seen	NULL
between	NULL
-869	NULL
CAT	NULL
and	NULL
-1.58	NULL
CAT	NULL
in	NULL
the	NULL
B95-8-converted	NULL
lines	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
EBV-responsive	NULL
element	NULL
was	NULL
not	NULL
functional	NULL
in	NULL
these	NULL
cell	NULL
lines	NULL
.	NULL

This	NULL
experiment	NULL
demonstrates	NULL
that	NULL
infection	NULL
of	NULL
EBV	NULL
~	NULL
B-cell	NULL
tumor	NULL
lines	NULL
does	NULL
not	NULL
drive	NULL
them	NULL
to	NULL
become	NULL
sufficiently	NULL
lymphoblastoid	NULL
in	NULL
phenotype	NULL
to	NULL
allow	NULL
the	NULL
EBV-responsive	NULL
element	NULL
to	NULL
function	NULL
.	NULL

We	NULL
conclude	NULL
,	NULL
therefore	NULL
,	NULL
that	NULL
EBV	NULL
inducibility	NULL
of	NULL
the	NULL
element	NULL
is	NULL
restricted	NULL
to	NULL
normal	NULL
B	NULL
cells	NULL
.	NULL

NF-	NULL
<	NULL
B	NULL
alone	NULL
is	NULL
insufficient	NULL
to	NULL
activate	NULL
the	NULL
element	NULL
.	NULL

The	NULL
EBV	NULL
-inducible	NULL
element	NULL
in	NULL
the	NULL
CD48	NULL
gene	NULL
contains	NULL
an	NULL
essential	NULL
NF-kB	NULL
site	NULL
,	NULL
and	NULL
EBV	NULL
LMP-1	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
activate	NULL
NF-kB	NULL
(	NULL
18	NULL
)	NULL
.	NULL

We	NULL
wished	NULL
to	NULL
confirm	NULL
the	NULL
latter	NULL
observation	NULL
in	NULL
lymphoid	NULL
cells	NULL
and	NULL
test	NULL
if	NULL
NF-	NULL
«	NULL
B	NULL
alone	NULL
was	NULL
sufficient	NULL
to	NULL
activate	NULL
the	NULL
EBV-inducible	NULL
element	NULL
in	NULL
the	NULL
EBV	NULL
~	NULL
B-cell	NULL
tumor	NULL
lines	NULL
.	NULL

A	NULL
construct	NULL
containing	NULL
two	NULL
copies	NULL
of	NULL
the	NULL
CD48	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
cloned	NULL
upstream	NULL
of	NULL
the	NULL
TK	NULL
CAT	NULL
promoter	NULL
(	NULL
pCD48	NULL
NF-	NULL
«	NULL
B	NULL
TK	NULL
CAT	NULL
)	NULL
showed	NULL
high	NULL
activity	NULL
in	NULL
[	NULL
B4	NULL
cells	NULL
and	NULL
low	NULL
activity	NULL
in	NULL
BJAB	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

8B	NULL
)	NULL
.	NULL

A	NULL
control	NULL
plasmid	NULL
(	NULL
mt	NULL
NF-	NULL
«	NULL
B	NULL
TK	NULL
CAT	NULL
)	NULL
,	NULL
containing	NULL
mutated	NULL
NF-	NULL
«	NULL
B	NULL
sites	NULL
,	NULL
was	NULL
completely	NULL
inactive	NULL
in	NULL
both	NULL
cell	NULL
lines	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
-1.58	NULL
CAT	NULL
had	NULL
no	NULL
detectable	NULL
activity	NULL
in	NULL
BJAB	NULL
cells	NULL
but	NULL
was	NULL
highly	NULL
active	NULL
in	NULL
1B4	NULL
cells	NULL
.	NULL

Co-transfection	NULL
of	NULL
an	NULL
LMP-1	NULL
expression	NULL
vector	NULL
(	NULL
pSV2	NULL
BNLF1	NULL
)	NULL
into	NULL
the	NULL
BJAB	NULL
cells	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
-1.58	NULL
CAT	NULL
construct	NULL
but	NULL
resulted	NULL
in	NULL
a	NULL
marked	NULL
transactivation	NULL
,	NULL
about	NULL
10-fold	NULL
,	NULL
of	NULL
the	NULL
pCD48	NULL
NF-	NULL
«	NULL
B	NULL
TK	NULL
CAT	NULL
construct	NULL
(	NULL
Fig	NULL
.	NULL

8B	NULL
)	NULL
and	NULL
of	NULL
other	NULL
con	NULL
structs	NULL
containing	NULL
NF-KB	NULL
sites	NULL
from	NULL
the	NULL
human	NULL
or	NULL
murine	NULL
Igx	NULL
loci	NULL
,	NULL
the	NULL
c-myc	NULL
gene	NULL
,	NULL
or	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
same	NULL
results	NULL
were	NULL
obtained	NULL
when	NULL
NF-kB	NULL
activity	NULL
was	NULL
induced	NULL
directly	NULL
,	NULL
via	NULL
expression	NULL
vectors	NULL
for	NULL
the	NULL
p50	NULL
and	NULL
p65	NULL
components	NULL
of	NULL
NF-kB	NULL
,	NULL
or	NULL
by	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
induction	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

No	NULL
transactivation	NULL
by	NULL
LMP-1	NULL
,	NULL
NF-kB	NULL
,	NULL
or	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
was	NULL
seen	NULL
when	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
sites	NULL
were	NULL
inactivated	NULL
by	NULL
specific	NULL
mutation	NULL
(	NULL
for	NULL
example	NULL
,	NULL
the	NULL
mt	NULL
NF-kB	NULL
TK	NULL
CAT	NULL
construct	NULL
)	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
experiments	NULL
demonstrate	NULL
that	NULL
LMP-1	NULL
can	NULL
induce	NULL
NF-KB	NULL
activity	NULL
in	NULL
human	NULL
B-lymphoid	NULL
cells	NULL
and	NULL
that	NULL
NF-xB	NULL
,	NULL
expressed	NULL
directly	NULL
or	NULL
indirectly	NULL
through	NULL
LMP	NULL
can	NULL
transactivate	NULL
the	NULL
CD48	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
.	NULL

NF-kB	NULL
alone	NULL
,	NULL
however	NULL
,	NULL
is	NULL
not	NULL
sufficient	NULL
to	NULL
activate	NULL
the	NULL
EBV-responsive	NULL
element	NULL
.	NULL

DISCUSSION	NULL
In	NULL
this	NULL
paper	NULL
,	NULL
we	NULL
report	NULL
on	NULL
the	NULL
identification	NULL
and	NULL
mapping	NULL
of	NULL
an	NULL
EBV	NULL
-responsive	NULL
element	NULL
within	NULL
the	NULL
upstream	NULL
region	NULL
of	NULL
the	NULL
CD48	NULL
gene	NULL
.	NULL

Furthermore	NULL
,	NULL
we	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
element	NULL
binds	NULL
a	NULL
nuclear	NULL
protein	NULL
complex	NULL
,	NULL
only	NULL
found	NULL
in	NULL
extracts	NULL
from	NULL
EBV	NULL
*	NULL
B-LCL	NULL
,	NULL
and	NULL
that	NULL
a	NULL
functional	NULL
NF-KB	NULL
site	NULL
is	NULL
an	NULL
essential	NULL
component	NULL
of	NULL
the	NULL
element	NULL
.	NULL

Since	NULL
NF-KB	NULL
is	NULL
a	NULL
classical	NULL
mediator	NULL
of	NULL
gene	NULL
regulation	NULL
during	NULL
B-cell	NULL
activation	NULL
,	NULL
this	NULL
observation	NULL
confirms	NULL
that	NULL
EBV	NULL
exploits	NULL
physiologic	NULL
pathways	NULL
to	NULL
alter	NULL
the	NULL
phenotype	NULL
of	NULL
resting	NULL
mature	NULL
B	NULL
cells	NULL
as	NULL
it	NULL
drives	NULL
them	NULL
to	NULL
become	NULL
proliferating	NULL
lymphoblasts	NULL
.	NULL

The	NULL
CD48	NULL
promoter	NULL
,	NULL
localized	NULL
between	NULL
positions	NULL
-234	NULL
and	NULL
-110	NULL
upstream	NULL
of	NULL
exon	NULL
1	NULL
,	NULL
was	NULL
only	NULL
active	NULL
in	NULL
lymphoid	NULL
cell	NULL
lines	NULL
.	NULL

However	NULL
,	NULL
the	NULL
promoter	NULL
is	NULL
negatively	NULL
regulated	NULL
in	NULL
lym-	NULL
Vou	NULL
.	NULL

69	NULL
,	NULL
1995	NULL
CD48	NULL
GENE	NULL
REGULATION	NULL
IN	NULL
EBV-IMMORTALIZED	NULL
B	NULL
CELLS	NULL
879	NULL
B	NULL
1.0	NULL
1.0	NULL
7	NULL
o.s-	NULL
I	NULL
Ass	NULL
cat	NULL
o.s	NULL
-	NULL
C	NULL
]	NULL
suas	NULL
é	NULL
71	NULL
;	NULL
>	NULL
[	NULL
C	NULL
]	NULL
«	NULL
see	NULL
cat	NULL
«	NULL
P	NULL
sas	NULL
aime	NULL
/	NULL
>	NULL
1B4	NULL
(	NULL
EBV+	NULL
)	NULL
/	NULL
/	NULL
3	NULL
os-	NULL
0.6	NULL
-	NULL
f	NULL
/	NULL
3	NULL
2	NULL
-	NULL
§	NULL
a	NULL
)	NULL
<	NULL
I	NULL
g	NULL
0.4-	NULL
0.4	NULL
é	NULL
cC	NULL
0.24	NULL
0.2	NULL
-	NULL
é	NULL
7	NULL
0.9	NULL
|	NULL
eee	NULL
-__-	NULL
,	NULL
wie	NULL
``	NULL
_	NULL
Bm	NULL
o	NULL
rza	NULL
P	NULL
F	NULL
BL41	NULL
-	NULL
BL41	NULL
B953	NULL
-	NULL
BJAB	NULL
-	NULL
BJAB	NULL
B953	NULL
-	NULL
IB4	NULL
mt	NULL
NFKB	NULL
CD43	NULL
NFKB	NULL
1.58	NULL
CAT	NULL
TK	NULL
CAT	NULL
TK	NULL
CAT	NULL
Cell	NULL
Line	NULL
Construct	NULL
FIG	NULL
.	NULL

8	NULL
.	NULL

(	NULL
A	NULL
)	NULL
The	NULL
EBV-responsive	NULL
element	NULL
does	NULL
not	NULL
function	NULL
in	NULL
in	NULL
vitro-infected	NULL
EBV~	NULL
BL	NULL
lines	NULL
.	NULL

The	NULL
bar	NULL
graph	NULL
shows	NULL
a	NULL
quantitative	NULL
comparison	NULL
of	NULL
relative	NULL
CAT	NULL
activities	NULL
following	NULL
transient	NULL
transfection	NULL
of	NULL
-1.58	NULL
CAT	NULL
or	NULL
deletion	NULL
construct	NULL
-869	NULL
CAT	NULL
into	NULL
EBV~	NULL
BL	NULL
cell	NULL
lines	NULL
BL41	NULL
and	NULL
BJAB	NULL
before	NULL
and	NULL
after	NULL
infection	NULL
with	NULL
the	NULL
B95-8	NULL
strain	NULL
of	NULL
EBV	NULL
.	NULL

The	NULL
EBV	NULL
*	NULL
B-LCL	NULL
IB4	NULL
was	NULL
included	NULL
as	NULL
a	NULL
control	NULL
to	NULL
demonstrate	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
EBV-responsive	NULL
element	NULL
.	NULL

The	NULL
experiment	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

(	NULL
B	NULL
)	NULL
EBV-encoded	NULL
LMP-1	NULL
induces	NULL
NF-	NULL
«	NULL
B	NULL
but	NULL
fails	NULL
to	NULL
transactivate	NULL
-1.58	NULL
CAT	NULL
.	NULL

The	NULL
bar	NULL
graph	NULL
shows	NULL
a	NULL
quantitative	NULL
comparison	NULL
of	NULL
relative	NULL
CAT	NULL
activities	NULL
following	NULL
transient	NULL
transfection	NULL
of	NULL
CAT	NULL
reporter	NULL
constructs	NULL
consisting	NULL
of	NULL
either	NULL
two	NULL
CD48	NULL
NF-	NULL
«	NULL
B	NULL
sites	NULL
upstream	NULL
of	NULL
the	NULL
TK	NULL
promoter	NULL
(	NULL
pCD48	NULL
NF-	NULL
«	NULL
B	NULL
TK	NULL
CAT	NULL
)	NULL
or	NULL
the	NULL
same	NULL
construct	NULL
but	NULL
with	NULL
two	NULL
mutated	NULL
NF-B	NULL
sites	NULL
(	NULL
mt	NULL
NF-xB	NULL
TK	NULL
CAT	NULL
)	NULL
or	NULL
the	NULL
-1.58	NULL
CAT	NULL
construct	NULL
.	NULL

Each	NULL
construct	NULL
was	NULL
transfected	NULL
into	NULL
the	NULL
EBV	NULL
~	NULL
line	NULL
BJAB	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
an	NULL
LMP-1	NULL
expression	NULL
vector	NULL
(	NULL
pSV2	NULL
BNLF1	NULL
}	NULL
or	NULL
into	NULL
the	NULL
EBV	NULL
*	NULL
B-LCL	NULL
IB4	NULL
as	NULL
a	NULL
control	NULL
.	NULL

The	NULL
experiment	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

2.	NULL
phoid	NULL
lines	NULL
by	NULL
elements	NULL
present	NULL
further	NULL
upstream	NULL
,	NULL
between	NULL
-599	NULL
and	NULL
-999	NULL
.	NULL

In	NULL
order	NULL
for	NULL
the	NULL
CD48	NULL
gene	NULL
to	NULL
be	NULL
expressed	NULL
,	NULL
the	NULL
transcriptional	NULL
silencers	NULL
need	NULL
to	NULL
be	NULL
overridden	NULL
,	NULL
and	NULL
the	NULL
positive	NULL
elements	NULL
required	NULL
for	NULL
this	NULL
activation	NULL
are	NULL
different	NULL
in	NULL
EBV	NULL
*	NULL
B-LCLs	NULL
and	NULL
EBV~	NULL
lymphoid	NULL
lines	NULL
.	NULL

The	NULL
element	NULL
required	NULL
to	NULL
restore	NULL
activity	NULL
in	NULL
the	NULL
EBV	NULL
*	NULL
B-LCLs	NULL
was	NULL
localized	NULL
between	NULL
positions	NULL
-1245	NULL
and	NULL
-1066	NULL
.	NULL

The	NULL
sequences	NULL
necessary	NULL
to	NULL
restore	NULL
activity	NULL
in	NULL
the	NULL
EBV	NULL
~	NULL
lymphoid	NULL
lines	NULL
have	NULL
not	NULL
been	NULL
mapped	NULL
since	NULL
they	NULL
are	NULL
not	NULL
present	NULL
in	NULL
the	NULL
largest	NULL
construct	NULL
that	NULL
we	NULL
have	NULL
tested	NULL
,	NULL
-1.58	NULL
CAT	NULL
.	NULL

From	NULL
these	NULL
observations	NULL
,	NULL
we	NULL
conclude	NULL
that	NULL
there	NULL
are	NULL
two	NULL
distinct	NULL
mechanisms	NULL
for	NULL
activating	NULL
the	NULL
CD48	NULL
gene	NULL
,	NULL
one	NULL
for	NULL
mature	NULL
resting	NULL
B	NULL
cells	NULL
,	NULL
which	NULL
is	NULL
exploited	NULL
by	NULL
EBV	NULL
,	NULL
and	NULL
another	NULL
,	NULL
exemplified	NULL
by	NULL
EBV	NULL
~-	NULL
lymphoid	NULL
tumor	NULL
lines	NULL
such	NULL
as	NULL
EBV	NULL
~	NULL
BL	NULL
.	NULL

This	NULL
presumably	NULL
reflects	NULL
the	NULL
fact	NULL
that	NULL
EBV~	NULL
BL	NULL
is	NULL
a	NULL
different	NULL
cell	NULL
type	NULL
from	NULL
the	NULL
mature	NULL
B	NULL
cell	NULL
that	NULL
gives	NULL
rise	NULL
to	NULL
the	NULL
EBV	NULL
*	NULL
B-LCL	NULL
.	NULL

BLs	NULL
are	NULL
believed	NULL
to	NULL
derive	NULL
from	NULL
the	NULL
germinal	NULL
center	NULL
centrocyte/centroblast	NULL
and	NULL
do	NULL
not	NULL
express	NULL
the	NULL
activated	NULL
phenotype	NULL
in	NULL
vivo	NULL
(	NULL
27	NULL
)	NULL
.	NULL

When	NULL
EBV	NULL
~	NULL
BL	NULL
cell	NULL
lines	NULL
are	NULL
infected	NULL
with	NULL
EBV	NULL
in	NULL
vitro	NULL
,	NULL
a	NULL
tiny	NULL
fraction	NULL
of	NULL
the	NULL
cells	NULL
become	NULL
stably	NULL
infected	NULL
,	NULL
and	NULL
these	NULL
cells	NULL
tend	NULL
to	NULL
move	NULL
toward	NULL
a	NULL
more	NULL
activated	NULL
blastoid	NULL
phenotype	NULL
(	NULL
7	NULL
,	NULL
41	NULL
,	NULL
42	NULL
)	NULL
.	NULL

There	NULL
is	NULL
a	NULL
great	NULL
deal	NULL
of	NULL
heter-ogeneity	NULL
,	NULL
between	NULL
cell	NULL
lines	NULL
and	NULL
between	NULL
clones	NULL
from	NULL
the	NULL
same	NULL
BL	NULL
line	NULL
,	NULL
in	NULL
the	NULL
degree	NULL
to	NULL
which	NULL
individual	NULL
markers	NULL
are	NULL
altered	NULL
in	NULL
their	NULL
expression	NULL
by	NULL
EBV	NULL
infection	NULL
.	NULL

It	NULL
is	NULL
apparent	NULL
that	NULL
genes	NULL
activated	NULL
by	NULL
infection	NULL
of	NULL
mature	NULL
resting	NULL
B	NULL
cells	NULL
may	NULL
be	NULL
regulated	NULL
differently	NULL
upon	NULL
infection	NULL
of	NULL
BL	NULL
cells	NULL
.	NULL

This	NULL
is	NULL
most	NULL
clearly	NULL
demonstrated	NULL
with	NULL
CD48	NULL
.	NULL

CD48	NULL
is	NULL
already	NULL
expressed	NULL
by	NULL
EBV	NULL
~	NULL
B-cell	NULL
lines	NULL
through	NULL
the	NULL
action	NULL
of	NULL
an	NULL
as	NULL
yet	NULL
unmapped	NULL
ele-ment	NULL
(	NULL
s	NULL
)	NULL
.	NULL

EBV	NULL
infection	NULL
of	NULL
these	NULL
cells	NULL
is	NULL
not	NULL
sufficient	NULL
to	NULL
activate	NULL
the	NULL
EBV-responsive	NULL
element	NULL
.	NULL

However	NULL
,	NULL
we	NULL
know	NULL
that	NULL
the	NULL
EBV	NULL
-responsive	NULL
element	NULL
functions	NULL
in	NULL
EBV	NULL
*	NULL
cells	NULL
that	NULL
are	NULL
truly	NULL
lymphoblastoid	NULL
in	NULL
phenotype	NULL
,	NULL
i.e	NULL
.	NULL

,	NULL
the	NULL
EBV	NULL
*	NULL
B	NULL
LCL	NULL
.	NULL

There	NULL
fore	NULL
,	NULL
we	NULL
can	NULL
conclude	NULL
that	NULL
EBV	NULL
infection	NULL
of	NULL
EBV~	NULL
B-cell	NULL
tumor	NULL
lines	NULL
fails	NULL
to	NULL
push	NULL
them	NULL
to	NULL
become	NULL
sufficiently	NULL
lymphoblastoid	NULL
in	NULL
character	NULL
as	NULL
to	NULL
allow	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
EBV-responsive	NULL
element	NULL
.	NULL

This	NULL
means	NULL
that	NULL
the	NULL
element	NULL
is	NULL
EBV	NULL
responsive	NULL
only	NULL
upon	NULL
infection	NULL
of	NULL
the	NULL
natural	NULL
target	NULL
for	NULL
EBV	NULL
,	NULL
the	NULL
resting	NULL
mature	NULL
B	NULL
cell	NULL
.	NULL

NF-xB	NULL
expressed	NULL
directly	NULL
or	NULL
via	NULL
LMP-1	NULL
can	NULL
transactivate	NULL
the	NULL
CD48	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
when	NULL
cotransfected	NULL
into	NULL
EBV	NULL
~	NULL
BLs	NULL
.	NULL

This	NULL
finding	NULL
suggests	NULL
a	NULL
role	NULL
for	NULL
LMP-1	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
CD48	NULL
by	NULL
EBV	NULL
,	NULL
yet	NULL
it	NULL
is	NULL
apparent	NULL
that	NULL
LMP-1	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
are	NULL
not	NULL
sufficient	NULL
to	NULL
transactivate	NULL
the	NULL
CD48	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
in	NULL
the	NULL
context	NULL
of	NULL
its	NULL
flanking	NULL
sequences	NULL
.	NULL

There	NULL
is	NULL
precedence	NULL
for	NULL
this	NULL
in	NULL
the	NULL
literature	NULL
,	NULL
where	NULL
several	NULL
studies	NULL
demonstrate	NULL
that	NULL
sequences	NULL
surrounding	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
can	NULL
influence	NULL
the	NULL
binding	NULL
and/or	NULL
function	NULL
of	NULL
NF-kB	NULL
,	NULL
for	NULL
example	NULL
,	NULL
with	NULL
the	NULL
interleukin-2	NULL
receptor	NULL
alpha	NULL
chain	NULL
(	NULL
8	NULL
)	NULL
,	NULL
beta	NULL
interferon	NULL
(	NULL
25	NULL
)	NULL
,	NULL
and	NULL
ELAM-1	NULL
genes	NULL
(	NULL
44	NULL
)	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
belongs	NULL
to	NULL
a	NULL
family	NULL
of	NULL
dimer-forming	NULL
,	NULL
ref	NULL
oncogene-related	NULL
proteins	NULL
found	NULL
in	NULL
most	NULL
cell	NULL
types	NULL
(	NULL
reviewed	NULL
in	NULL
references	NULL
4	NULL
and	NULL
17	NULL
)	NULL
.	NULL

The	NULL
nuclear	NULL
protein	NULL
complex	NULL
in	NULL
EBV	NULL
*	NULL
B-LCLs	NULL
that	NULL
binds	NULL
to	NULL
the	NULL
EBV-responsive	NULL
element	NULL
of	NULL
CD48	NULL
contains	NULL
NF-kB1	NULL
p	NULL
(	NULL
50	NULL
)	NULL
probably	NULL
as	NULL
a	NULL
homodimer	NULL
.	NULL

This	NULL
was	NULL
surprising	NULL
,	NULL
since	NULL
the	NULL
EBV-responsive	NULL
element	NULL
is	NULL
positively	NULL
transactivating	NULL
and	NULL
it	NULL
is	NULL
generally	NULL
believed	NULL
that	NULL
p50	NULL
ho-modimers	NULL
do	NULL
not	NULL
transactivate	NULL
promoters	NULL
(	NULL
17	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
other	NULL
components	NULL
of	NULL
the	NULL
complex	NULL
are	NULL
not	NULL
yet	NULL
clear	NULL
.	NULL

For	NULL
example	NULL
,	NULL
we	NULL
have	NULL
noticed	NULL
that	NULL
the	NULL
DNase	NULL
I	NULL
footprint	NULL
also	NULL
includes	NULL
a	NULL
perfect	NULL
binding	NULL
site	NULL
for	NULL
the	NULL
Ets	NULL
family	NULL
member	NULL
Pea-3	NULL
(	NULL
AGG	NULL
AAG	NULL
)	NULL
and	NULL
have	NULL
,	NULL
on	NULL
occasion	NULL
,	NULL
seen	NULL
evidence	NULL
for	NULL
a	NULL
second	NULL
footprint	NULL
,	NULL
about	NULL
70	NULL
to	NULL
80	NULL
bp	NULL
3	NULL
'	NULL
of	NULL
the	NULL
NF-kB	NULL
site	NULL
,	NULL
that	NULL
also	NULL
includes	NULL
a	NULL
potential	NULL
Ets	NULL
binding	NULL
site	NULL
(	NULL
see	NULL
,	NULL
for	NULL
example	NULL
,	NULL
the	NULL
20-pg-loaded	NULL
lane	NULL
for	NULL
the	NULL
wild-type	NULL
probe	NULL
in	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
.	NULL

How	NULL
880	NULL
KLAMAN	NULL
AND	NULL
THORLEY-LAWSON	NULL
ever	NULL
,	NULL
to	NULL
date	NULL
we	NULL
have	NULL
been	NULL
unable	NULL
to	NULL
demonstrate	NULL
specific	NULL
binding	NULL
of	NULL
Ets	NULL
proteins	NULL
to	NULL
the	NULL
EBV-responsive	NULL
element	NULL
.	NULL

NF-	NULL
«	NULL
B/Rel	NULL
family	NULL
members	NULL
are	NULL
expressed	NULL
in	NULL
the	NULL
cytoplasm	NULL
as	NULL
inactive	NULL
complexes	NULL
in	NULL
association	NULL
with	NULL
a	NULL
member	NULL
of	NULL
the	NULL
IxB	NULL
family	NULL
.	NULL

Paradigmatically	NULL
,	NULL
signals	NULL
emanating	NULL
from	NULL
the	NULL
cell	NULL
membrane	NULL
lead	NULL
to	NULL
phosphorylation	NULL
and	NULL
dissociation	NULL
of	NULL
IxB	NULL
from	NULL
the	NULL
complex	NULL
,	NULL
resulting	NULL
in	NULL
the	NULL
migration	NULL
of	NULL
active	NULL
NF-kB	NULL
to	NULL
the	NULL
nucleus	NULL
.	NULL

It	NULL
is	NULL
not	NULL
surprising	NULL
therefore	NULL
,	NULL
that	NULL
LMP-1	NULL
should	NULL
be	NULL
involved	NULL
in	NULL
activating	NULL
NF-	NULL
«	NULL
B	NULL
since	NULL
LMP-1	NULL
is	NULL
localized	NULL
in	NULL
the	NULL
plasma	NULL
membrane	NULL
and	NULL
,	NULL
like	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
is	NULL
regulated	NULL
in	NULL
its	NULL
activity	NULL
by	NULL
serine/threonine	NULL
phosphorylation	NULL
(	NULL
32	NULL
)	NULL
.	NULL

LMP-1	NULL
is	NULL
the	NULL
only	NULL
EBV	NULL
latent	NULL
protein	NULL
clearly	NULL
demonstrated	NULL
to	NULL
act	NULL
as	NULL
a	NULL
dominant	NULL
oncogene	NULL
(	NULL
2	NULL
,	NULL
40	NULL
)	NULL
and	NULL
is	NULL
essential	NULL
for	NULL
the	NULL
immortalization	NULL
of	NULL
normal	NULL
,	NULL
mature	NULL
,	NULL
resting	NULL
B	NULL
cells	NULL
(	NULL
20	NULL
)	NULL
.	NULL

It	NULL
is	NULL
inactivated	NULL
by	NULL
phosphorylation	NULL
at	NULL
threonine	NULL
324	NULL
and	NULL
also	NULL
has	NULL
an	NULL
extremely	NULL
short	NULL
half-life	NULL
(	NULL
2	NULL
to	NULL
3	NULL
h	NULL
)	NULL
(	NULL
2	NULL
,	NULL
30	NULL
)	NULL
,	NULL
being	NULL
turned	NULL
over	NULL
by	NULL
a	NULL
specific	NULL
proteolytic	NULL
cleavage	NULL
event	NULL
that	NULL
also	NULL
inactivates	NULL
the	NULL
protein	NULL
(	NULL
31	NULL
)	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
the	NULL
same	NULL
specific	NULL
serine/threonine	NULL
kinase	NULL
phosphorylates	NULL
NF-kB	NULL
and	NULL
LMP-1	NULL
,	NULL
leading	NULL
to	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
inactivation	NULL
of	NULL
LMP-1	NULL
,	NULL
which	NULL
would	NULL
then	NULL
be	NULL
turned	NULL
over	NULL
through	NULL
cleavage	NULL
.	NULL

The	NULL
nature	NULL
of	NULL
the	NULL
kinase	NULL
,	NULL
how	NULL
LMP	NULL
activates	NULL
it	NULL
,	NULL
and	NULL
whether	NULL
NF-B	NULL
is	NULL
the	NULL
only	NULL
pathway	NULL
of	NULL
LMP	NULL
signaling	NULL
remain	NULL
to	NULL
be	NULL
ascertained	NULL
.	NULL

In	NULL
conclusion	NULL
,	NULL
the	NULL
analysis	NULL
presented	NULL
here	NULL
demonstrates	NULL
that	NULL
the	NULL
CD48	NULL
gene	NULL
is	NULL
a	NULL
good	NULL
model	NULL
for	NULL
studying	NULL
cellular	NULL
genes	NULL
that	NULL
are	NULL
differentially	NULL
regulated	NULL
by	NULL
EBV	NULL
in	NULL
normal	NULL
and	NULL
EBV	NULL
~	NULL
B-cell	NULL
tumor	NULL
lines	NULL
.	NULL

We	NULL
are	NULL
now	NULL
attempting	NULL
to	NULL
better	NULL
characterize	NULL
the	NULL
mechanism	NULL
of	NULL
signaling	NULL
by	NULL
LMP-1	NULL
and	NULL
what	NULL
other	NULL
factors	NULL
cooperate	NULL
with	NULL
LMP-1	NULL
to	NULL
activate	NULL
the	NULL
CD48	NULL
gene	NULL
in	NULL
normal	NULL
B	NULL
cells	NULL
.	NULL

The	NULL
CD48	NULL
NF-kB	NULL
site	NULL
is	NULL
LMP-1/NF-	NULL
«	NULL
B	NULL
inducible	NULL
in	NULL
EBV	NULL
~	NULL
B-cell	NULL
tumor	NULL
lines	NULL
,	NULL
but	NULL
the	NULL
entire	NULL
EBV-responsive	NULL
element	NULL
is	NULL
not	NULL
.	NULL

By	NULL
systematically	NULL
adding	NULL
back	NULL
sequences	NULL
to	NULL
the	NULL
CD48	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
,	NULL
it	NULL
should	NULL
be	NULL
possible	NULL
to	NULL
identify	NULL
the	NULL
DNA	NULL
sequences	NULL
that	NULL
confer	NULL
this	NULL
unresponsiveness	NULL
.	NULL

Identification	NULL
of	NULL
these	NULL
sequences	NULL
should	NULL
allow	NULL
us	NULL
to	NULL
distinguish	NULL
whether	NULL
unresponsiveness	NULL
in	NULL
the	NULL
EBV~	NULL
B-cell	NULL
tumor	NULL
lines	NULL
is	NULL
due	NULL
to	NULL
the	NULL
presence	NULL
of	NULL
negatively	NULL
regulating	NULL
factors	NULL
or	NULL
the	NULL
absence	NULL
of	NULL
positively	NULL
regulating	NULL
factors	NULL
.	NULL

Similarly	NULL
,	NULL
the	NULL
CD48	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
does	NULL
not	NULL
bind	NULL
nucleoprotein	NULL
complexes	NULL
that	NULL
are	NULL
specific	NULL
to	NULL
EBV	NULL
*	NULL
B-LCLs	NULL
,	NULL
whereas	NULL
the	NULL
entire	NULL
EBV-responsive	NULL
element	NULL
does	NULL
.	NULL

By	NULL
adding	NULL
back	NULL
sequences	NULL
,	NULL
it	NULL
should	NULL
also	NULL
be	NULL
possible	NULL
to	NULL
identify	NULL
the	NULL
elements	NULL
required	NULL
to	NULL
impose	NULL
EBV	NULL
specificity	NULL
on	NULL
the	NULL
CD48	NULL
NF-KB	NULL
site	NULL
.	NULL

These	NULL
sites	NULL
may	NULL
be	NULL
the	NULL
same	NULL
as	NULL
those	NULL
that	NULL
cause	NULL
unresponsiveness	NULL
in	NULL
the	NULL
EBV~	NULL
B-cell	NULL
tumor	NULL
lines	NULL
.	NULL

Once	NULL
these	NULL
sites	NULL
and	NULL
factors	NULL
are	NULL
identified	NULL
,	NULL
it	NULL
should	NULL
be	NULL
possible	NULL
to	NULL
proceed	NULL
to	NULL
reconstruct	NULL
the	NULL
entire	NULL
functional	NULL
EBV-responsive	NULL
element	NULL
in	NULL
the	NULL
EBV	NULL
~	NULL
B-cell	NULL
tumor	NULL
lines	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
gratefully	NULL
thank	NULL
Nancy	NULL
Rice	NULL
and	NULL
Ulrich	NULL
Sicbenlist	NULL
for	NULL
providing	NULL
antisera	NULL
,	NULL
Emily	NULL
Miyashita	NULL
for	NULL
assistance	NULL
in	NULL
preparation	NULL
of	NULL
deletion	NULL
plasmids	NULL
,	NULL
and	NULL
Gerry	NULL
Parker	NULL
for	NULL
photographic	NULL
expertise	NULL
.	NULL

We	NULL
also	NULL
thank	NULL
Ananda	NULL
Roy	NULL
,	NULL
Scott	NULL
Brodeur	NULL
,	NULL
and	NULL
Marlene	NULL
Klaman	NULL
for	NULL
critical	NULL
comments	NULL
and	NULL
suggestions	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
Public	NULL
Health	NULL
Service	NULL
grants	NULL
Al	NULL
18757	NULL
and	NULL
CA	NULL
31893	NULL
from	NULL
the	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Abmayer	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
J.	NULL
L.	NULL
Workman	NULL
.	NULL

1991	NULL
.	NULL

Preparation	NULL
of	NULL
nuclear	NULL
and	NULL
cyto-plasmic	NULL
extracts	NULL
from	NULL
mammalian	NULL
cells	NULL
,	NULL
p.	NULL
12.1.1-12.1.7	NULL
.	NULL

In	NULL
F.	NULL
M.	NULL
Ausubel	NULL
,	NULL
R.	NULL
Brent	NULL
,	NULL
R.	NULL
E.	NULL
Kingston	NULL
,	NULL
D.	NULL
D.	NULL
Moore	NULL
,	NULL
J.	NULL
G.	NULL
Seidman	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Smith	NULL
,	NULL
and	NULL
K.	NULL
Struhl	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Current	NULL
protocols	NULL
in	NULL
molecular	NULL
biology	NULL
,	NULL
vol	NULL
.	NULL

2	NULL
.	NULL

John	NULL
Wiley	NULL
&	NULL
Sons	NULL
,	NULL
New	NULL
York	NULL
.	NULL

2	NULL
.	NULL

Baichwal	NULL
,	NULL
V.	NULL
R.	NULL
,	NULL
and	NULL
B.	NULL
Sugden	NULL
.	NULL

1988	NULL
.	NULL

Transformation	NULL
of	NULL
Balb	NULL
3T3	NULL
cells	NULL
by	NULL
the	NULL
BNLFI1	NULL
gene	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

Oncogene	NULL
2:461-467	NULL
.	NULL

3	NULL
.	NULL

Baltimore	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
R.	NULL
Sen.	NULL
1986	NULL
.	NULL

Inducibility	NULL
of	NULL
«	NULL
immunoglobulin	NULL
enhancer-binding	NULL
protein	NULL
NF-	NULL
«	NULL
B	NULL
by	NULL
a	NULL
posttranslational	NULL
mechanism	NULL
.	NULL

Cell	NULL
47:921-928	NULL
.	NULL

4	NULL
.	NULL

Bours	NULL
,	NULL
V.	NULL
,	NULL
G.	NULL
Franzoso	NULL
,	NULL
K.	NULL
Brown	NULL
,	NULL
S.	NULL
Park	NULL
,	NULL
V.	NULL
Azarenko	NULL
,	NULL
M.	NULL
Tomita-Yamagu-	NULL
10	NULL
.	NULL

11	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

J.	NULL
ViroL	NULL
.	NULL

chi	NULL
,	NULL
K.	NULL
Kelly	NULL
,	NULL
and	NULL
U.	NULL
Siebenlist	NULL
.	NULL

1992	NULL
.	NULL

Lymphocyte	NULL
activation	NULL
and	NULL
the	NULL
family	NULL
of	NULL
NF-kappa	NULL
B	NULL
transcription	NULL
factor	NULL
complexes	NULL
.	NULL

Curr	NULL
.	NULL

Top	NULL
.	NULL

Microbiol	NULL
.	NULL

Immunol	NULL
.	NULL

182:411-420.	NULL
.	NULL

Cann	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
Y.	NULL
Koyanagi	NULL
,	NULL
and	NULL
I.	NULL
S.	NULL
Y.	NULL
Chen	NULL
.	NULL

1988	NULL
.	NULL

High	NULL
efficiency	NULL
transfection	NULL
of	NULL
primary	NULL
human	NULL
lymphocytes	NULL
and	NULL
studies	NULL
of	NULL
gene	NULL
expression	NULL
.	NULL

Oncogene	NULL
3:123-128.	NULL
.	NULL

Clark	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
and	NULL
P.	NULL
J	NULL
.	NULL

Lane	NULL
.	NULL

1991	NULL
.	NULL

Regulation	NULL
of	NULL
human	NULL
B-cell	NULL
activation	NULL
and	NULL
adhesion	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

9:97-127.	NULL
.	NULL

Cordier	NULL
,	NULL
M.	NULL
,	NULL
A.	NULL
Calender	NULL
,	NULL
M.	NULL
Billaud	NULL
,	NULL
U.	NULL
Zimber	NULL
,	NULL
G.	NULL
Rousselet	NULL
,	NULL
O.	NULL
Pavlish	NULL
,	NULL
J.	NULL
Banchereau	NULL
,	NULL
T.	NULL
Tursz	NULL
,	NULL
G.	NULL
W.	NULL
Bornkamm	NULL
,	NULL
and	NULL
G.	NULL
M.	NULL
Lenoir	NULL
.	NULL

1990	NULL
.	NULL

Stable	NULL
transfection	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
nuclear	NULL
antigen	NULL
2	NULL
in	NULL
lymphoma	NULL
cells	NULL
containing	NULL
the	NULL
EBV	NULL
P3HR1	NULL
genome	NULL
induces	NULL
expression	NULL
of	NULL
B-cell	NULL
activation	NULL
molecules	NULL
CD21	NULL
and	NULL
CD23	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:1002-1013.	NULL
.	NULL

Cross	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
N.	NULL
F.	NULL
Halden	NULL
,	NULL
M.	NULL
J.	NULL
Lenardo	NULL
,	NULL
and	NULL
W.	NULL
J.	NULL
Leonard	NULL
.	NULL

1989	NULL
.	NULL

Func-	NULL
tionally	NULL
distinct	NULL
NF-kB	NULL
binding	NULL
sites	NULL
in	NULL
the	NULL
immunoglobulin	NULL
x	NULL
and	NULL
IL-2	NULL
receptor	NULL
«	NULL
chain	NULL
genes	NULL
.	NULL

Science	NULL
244:466-469.	NULL
.	NULL

Dugas	NULL
,	NULL
B.	NULL
,	NULL
J.	NULL
F.	NULL
Delfraissy	NULL
,	NULL
A.	NULL
Calenda	NULL
,	NULL
M.	NULL
Peuchmaur	NULL
,	NULL
C.	NULL
Wallon	NULL
,	NULL
M.	NULL
T.	NULL
Rannou	NULL
,	NULL
and	NULL
P.	NULL
Galanaud	NULL
.	NULL

1988	NULL
.	NULL

Activation	NULL
and	NULL
infection	NULL
of	NULL
B-cells	NULL
by	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

Role	NULL
of	NULL
calcium	NULL
mobilization	NULL
and	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
translocation	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

141:4344-4351	NULL
.	NULL

Duyao	NULL
,	NULL
M.	NULL
P.	NULL
,	NULL
D.	NULL
J.	NULL
Kessler	NULL
,	NULL
D.	NULL
B.	NULL
Spicer	NULL
,	NULL
C.	NULL
Bartholomew	NULL
,	NULL
J.	NULL
C.	NULL
Cleveland	NULL
,	NULL
M.	NULL
Siekevitz	NULL
,	NULL
and	NULL
G.	NULL
E.	NULL
Sonenshein	NULL
.	NULL

1992	NULL
.	NULL

Transactivation	NULL
of	NULL
the	NULL
c-myc	NULL
promoter	NULL
by	NULL
human	NULL
T	NULL
cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
tax	NULL
is	NULL
mediated	NULL
by	NULL
NFkB	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267:16288-16291	NULL
.	NULL

Epstein	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
and	NULL
B.	NULL
G.	NULL
Achong	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

.	NULL

1986	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
:	NULL
recent	NULL
advances	NULL
.	NULL

Wiley	NULL
Medical	NULL
Publications	NULL
,	NULL
New	NULL
York	NULL
.	NULL

.	NULL

Faisst	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
S.	NULL
Meyer	NULL
.	NULL

1992	NULL
.	NULL

Compilation	NULL
of	NULL
vertebrate-encoded	NULL
transcrip-	NULL
tion	NULL
factors	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

20:3-26	NULL
.	NULL

Fisher	NULL
,	NULL
R.	NULL
C.	NULL
,	NULL
and	NULL
D.	NULL
A.	NULL
Thorley-Lawson	NULL
.	NULL

1991	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus-inducible	NULL
gene	NULL
encoding	NULL
the	NULL
human	NULL
leukocyte	NULL
adhesion	NULL
and	NULL
activation	NULL
antigen	NULL
Blast-1	NULL
(	NULL
CD48	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

11:1614-1623	NULL
.	NULL

Fisher	NULL
,	NULL
R.	NULL
C.	NULL
,	NULL
and	NULL
D.	NULL
A.	NULL
Thorley-Lawson	NULL
.	NULL

1993	NULL
.	NULL

Unpublished	NULL
data	NULL
.	NULL

Gorman	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
L.	NULL
F.	NULL
Moffat	NULL
,	NULL
and	NULL
B.	NULL
H.	NULL
Howard	NULL
.	NULL

1982	NULL
.	NULL

Recombinant	NULL
genomes	NULL
which	NULL
express	NULL
chloramphenicol	NULL
acetyltransferase	NULL
in	NULL
mammalian	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

2:1044-1051	NULL
.	NULL

Graham	NULL
,	NULL
F.	NULL
L.	NULL
,	NULL
and	NULL
A.	NULL
J.	NULL
van	NULL
der	NULL
Eb	NULL
.	NULL

1973	NULL
.	NULL

A	NULL
new	NULL
technique	NULL
for	NULL
the	NULL
assay	NULL
of	NULL
infectivity	NULL
of	NULL
human	NULL
adenovirus	NULL
5	NULL
DNA	NULL
.	NULL

Virology	NULL
52:456-467	NULL
.	NULL

Grilli	NULL
,	NULL
M.	NULL
,	NULL
J.	NULL
J.	NULL
Chiu	NULL
,	NULL
and	NULL
M.	NULL
J.	NULL
Lenardo	NULL
.	NULL

1993	NULL
.	NULL

NF-kappa	NULL
B	NULL
and	NULL
Rel	NULL
:	NULL
participants	NULL
in	NULL
a	NULL
multiform	NULL
transcriptional	NULL
regulatory	NULL
system	NULL
.	NULL

Int	NULL
.	NULL

Rev	NULL
.	NULL

Cytol	NULL
.	NULL

143:1-62	NULL
.	NULL

Hammarskjold	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
and	NULL
M.	NULL
C.	NULL
Simurda	NULL
.	NULL

1992	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
latent	NULL
membrane	NULL
protein	NULL
transactivates	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
long	NULL
terminal	NULL
repeat	NULL
through	NULL
induction	NULL
of	NULL
NF-kB	NULL
activity	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:6496-6501	NULL
.	NULL

Hammerschmidt	NULL
,	NULL
W.	NULL
,	NULL
and	NULL
B.	NULL
Sugden	NULL
.	NULL

1989	NULL
.	NULL

Genetic	NULL
analysis	NULL
of	NULL
immortalizing	NULL
functions	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
in	NULL
human	NULL
B	NULL
lymphocytes	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
340:393-397	NULL
.	NULL

Kaye	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
K.	NULL
M.	NULL
Izumi	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1993	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
latent	NULL
membrane	NULL
protein	NULL
1	NULL
is	NULL
essential	NULL
for	NULL
B-lymphocyte	NULL
growth	NULL
transformation	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90:9150-9154	NULL
.	NULL

Kintner	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
B.	NULL
Sugden	NULL
.	NULL

1981	NULL
.	NULL

Identification	NULL
of	NULL
antigenic	NULL
determinants	NULL
unique	NULL
to	NULL
the	NULL
surfaces	NULL
of	NULL
cells	NULL
transformed	NULL
by	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
294:458-460	NULL
.	NULL

Lacy	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
H.	NULL
Rudnick	NULL
.	NULL

1992	NULL
.	NULL

Transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
human	NULL
IgE	NULL
receptor	NULL
(	NULL
FegRII/CD23	NULL
)	NULL
by	NULL
EBV	NULL
:	NULL
identification	NULL
of	NULL
EBV-responsive	NULL
regulatory	NULL
elements	NULL
in	NULL
intron	NULL
1	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

148:1554-1560	NULL
.	NULL

Lane	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Ledbetter	NULL
,	NULL
F.	NULL
M.	NULL
McConnell	NULL
,	NULL
K.	NULL
Draves	NULL
,	NULL
J.	NULL
Deans	NULL
,	NULL
G.	NULL
L.	NULL
Schieven	NULL
,	NULL
and	NULL
E.	NULL
A.	NULL
Clark	NULL
,	NULL
1991	NULL
.	NULL

The	NULL
role	NULL
of	NULL
tyrosine	NULL
phosphorylation	NULL
in	NULL
signal	NULL
transduction	NULL
through	NULL
surface	NULL
Ig	NULL
in	NULL
human	NULL
B-cells	NULL
:	NULL
inhibition	NULL
of	NULL
tyrosine	NULL
phosphorylation	NULL
prevents	NULL
intracellular	NULL
calcium	NULL
release	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

146:715-722	NULL
.	NULL

Lane	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
M.	NULL
A.	NULL
Valentine	NULL
,	NULL
T.	NULL
Barret	NULL
,	NULL
F.	NULL
McConnell	NULL
,	NULL
K.	NULL
E.	NULL
Meier	NULL
,	NULL
and	NULL
E.	NULL
A.	NULL
Clark	NULL
.	NULL

1990	NULL
.	NULL

Surface	NULL
molecules	NULL
and	NULL
signal	NULL
transduction	NULL
events	NULL
in	NULL
human	NULL
B	NULL
cells	NULL
,	NULL
p.	NULL
117-143	NULL
.	NULL

In	NULL
J.	NULL
C.	NULL
Cambier	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Ligands	NULL
,	NULL
receptors	NULL
,	NULL
and	NULL
signal	NULL
transduction	NULL
in	NULL
regulation	NULL
of	NULL
lymphocyte	NULL
function	NULL
.	NULL

American	NULL
Society	NULL
for	NULL
Microbiology	NULL
,	NULL
Washington	NULL
,	NULL
D.C.	NULL
.	NULL

Lenardo	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
C.	NULL
M.	NULL
Fan	NULL
,	NULL
T.	NULL
Maniatis	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
involvement	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
B-interferon	NULL
gene	NULL
regulation	NULL
reveals	NULL
its	NULL
role	NULL
as	NULL
a	NULL
widely	NULL
inducible	NULL
mediator	NULL
of	NULL
signal	NULL
transduction	NULL
.	NULL

Cell	NULL
57:287-294	NULL
.	NULL

Ling	NULL
,	NULL
P.	NULL
D.	NULL
,	NULL
J.	NULL
J.	NULL
Hsieh	NULL
,	NULL
I.	NULL
K.	NULL
Ruf	NULL
,	NULL
D.	NULL
R.	NULL
Rawlins	NULL
,	NULL
and	NULL
S.	NULL
D.	NULL
Hayward	NULL
.	NULL

1994	NULL
.	NULL

EBNA-2	NULL
upregulation	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
latency	NULL
promoters	NULL
and	NULL
the	NULL
cellular	NULL
CD23	NULL
promoter	NULL
utilizes	NULL
a	NULL
common	NULL
targeting	NULL
intermediate	NULL
,	NULL
CBF-1	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

68:5375-5383	NULL
.	NULL

MacLennan	NULL
,	NULL
I.	NULL
C.	NULL
M.	NULL
,	NULL
Y.	NULL
L.	NULL
Liu	NULL
,	NULL
and	NULL
N.	NULL
R.	NULL
Ling	NULL
.	NULL

1988	NULL
.	NULL

B-cell	NULL
proliferation	NULL
in	NULL
follicles	NULL
,	NULL
germinal	NULL
centre	NULL
formation	NULL
and	NULL
the	NULL
site	NULL
of	NULL
neoplastic	NULL
transformation	NULL
in	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
.	NULL

Curr	NULL
.	NULL

Top	NULL
.	NULL

Microbiol	NULL
.	NULL

Immunol	NULL
.	NULL

141:138-148	NULL
.	NULL

Maxam	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
and	NULL
W.	NULL
Gilbert	NULL
.	NULL

1980	NULL
.	NULL

Sequencing	NULL
end-labeled	NULL
DNA	NULL
with	NULL
base-specific	NULL
chemical	NULL
cleavages	NULL
.	NULL

Methods	NULL
Enzymol	NULL
.	NULL

65:499-560	NULL
.	NULL

Miller	NULL
,	NULL
G.	NULL
1990	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
:	NULL
biology	NULL
,	NULL
pathogenesis	NULL
and	NULL
medical	NULL
as-pects	NULL
,	NULL
p.	NULL
1921-1958	NULL
.	NULL

In	NULL
B.	NULL
N.	NULL
Fields	NULL
et	NULL
al	NULL
.	NULL

(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Virology	NULL
,	NULL
2nd	NULL
ed	NULL
.	NULL

Raven	NULL
Press	NULL
,	NULL
New	NULL
York	NULL
.	NULL

Moorthy	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
D.	NULL
A.	NULL
Thorley-Lawson	NULL
.	NULL

1990	NULL
.	NULL

Processing	NULL
of	NULL
the	NULL
Epstein	NULL
Vou	NULL
.	NULL

69	NULL
,	NULL
1995	NULL
31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

Barr	NULL
virus-encoded	NULL
latent	NULL
membrane	NULL
protein	NULL
p63/LMP	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:829-837	NULL
.	NULL

Moorthy	NULL
,	NULL
R.	NULL
K.	NULL
,	NULL
and	NULL
D.	NULL
A.	NULL
Thorley-Lawson	NULL
.	NULL

1993	NULL
.	NULL

All	NULL
three	NULL
domains	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus-encoded	NULL
latent	NULL
membrane	NULL
protein	NULL
(	NULL
LMP-1	NULL
)	NULL
are	NULL
required	NULL
for	NULL
transformation	NULL
of	NULL
Rat-1	NULL
fibroblasts	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

67:1638-1646	NULL
.	NULL

Moorthy	NULL
,	NULL
R.	NULL
K.	NULL
,	NULL
and	NULL
D.	NULL
A.	NULL
Thorley-Lawson	NULL
.	NULL

1993	NULL
.	NULL

Biochemical	NULL
,	NULL
genetic	NULL
,	NULL
and	NULL
functional	NULL
analysis	NULL
of	NULL
the	NULL
phosphorylation	NULL
sites	NULL
on	NULL
the	NULL
Epstein-Barr	NULL
virus-encoded	NULL
,	NULL
oncogenic	NULL
,	NULL
latent	NULL
membrane	NULL
protein	NULL
LMP-1	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

67:2637-2645	NULL
.	NULL

Pope	NULL
,	NULL
J.	NULL
H.	NULL
1979	NULL
.	NULL

Transformation	NULL
by	NULL
the	NULL
virus	NULL
in	NULL
vitro	NULL
,	NULL
p.	NULL
205-223	NULL
.	NULL

In	NULL
M.	NULL
A.	NULL
Epstein	NULL
and	NULL
B.	NULL
G.	NULL
Achong	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
The	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

Springer-Verlag	NULL
,	NULL
New	NULL
York	NULL
.	NULL

Rosenthal	NULL
,	NULL
N.	NULL
1987	NULL
.	NULL

Identification	NULL
of	NULL
regulatory	NULL
elements	NULL
of	NULL
cloned	NULL
genes	NULL
with	NULL
functional	NULL
assays	NULL
.	NULL

Methods	NULL
Enzymol	NULL
.	NULL

152:704-720	NULL
.	NULL

Thorley-Lawson	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
and	NULL
C.	NULL
Ianelli	NULL
.	NULL

Unpublished	NULL
data	NULL
.	NULL

Thorley-Lawson	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
and	NULL
K.	NULL
P.	NULL
Mann	NULL
.	NULL

1985	NULL
.	NULL

Early	NULL
events	NULL
in	NULL
Epstein-Barr	NULL
virus	NULL
infection	NULL
provide	NULL
a	NULL
model	NULL
for	NULL
B-cell	NULL
activation	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

162:45-59	NULL
.	NULL

Thorley-Lawson	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
L.	NULL
M.	NULL
Nadler	NULL
,	NULL
A.	NULL
K.	NULL
Bhan	NULL
,	NULL
and	NULL
R.	NULL
T.	NULL
Schooley	NULL
.	NULL

1985	NULL
.	NULL

Blast-2	NULL
(	NULL
EBVCS	NULL
)	NULL
,	NULL
an	NULL
early	NULL
cell	NULL
surface	NULL
marker	NULL
of	NULL
human	NULL
B-cell	NULL
activation	NULL
,	NULL
is	NULL
superinduced	NULL
by	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

134:3007-3012	NULL
.	NULL

Thorley-Lawson	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
R.	NULL
T.	NULL
Schooley	NULL
,	NULL
A.	NULL
K.	NULL
Bhan	NULL
,	NULL
and	NULL
L.	NULL
M.	NULL
Nadler	NULL
.	NULL

1982	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
superinduces	NULL
a	NULL
new	NULL
human	NULL
B-cell	NULL
differentiation	NULL
antigen	NULL
(	NULL
B-last-1	NULL
)	NULL
expressed	NULL
on	NULL
transformed	NULL
lymphoblasts	NULL
.	NULL

Cell	NULL
30:415-425	NULL
.	NULL

Tompkinson	NULL
,	NULL
B.	NULL
,	NULL
E.	NULL
Robertson	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1993	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
nuclear	NULL
proteins	NULL
EBNA-3A	NULL
and	NULL
EBNA-3C	NULL
are	NULL
essential	NULL
for	NULL
B-lymphocyte	NULL
growth	NULL
CD48	NULL
GENE	NULL
REGULATION	NULL
IN	NULL
EBV-IMMORTALIZED	NULL
B	NULL
CELLS	NULL
40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

881	NULL
transformation	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

67:2014-2025	NULL
.	NULL

Wang	NULL
,	NULL
D.	NULL
,	NULL
D.	NULL
Liebowitz	NULL
,	NULL
and	NULL
E.	NULL
Kief	NULL
.	NULL

1985	NULL
.	NULL

An	NULL
EBV	NULL
membrane	NULL
protein	NULL
expressed	NULL
in	NULL
immortalized	NULL
lymphocytes	NULL
transforms	NULL
established	NULL
rodent	NULL
cells	NULL
.	NULL

Cell	NULL
43:831-840	NULL
.	NULL

Wang	NULL
,	NULL
D.	NULL
,	NULL
D.	NULL
Liebowitz	NULL
,	NULL
F.	NULL
Wang	NULL
,	NULL
C.	NULL
Gregory	NULL
,	NULL
A.	NULL
Rickinson	NULL
,	NULL
R.	NULL
Larson	NULL
,	NULL
T.	NULL
Springer	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1988	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
latent	NULL
membrane	NULL
protein	NULL
alters	NULL
the	NULL
human	NULL
B-lymphocyte	NULL
phenotype	NULL
:	NULL
deletion	NULL
of	NULL
the	NULL
amino	NULL
terminus	NULL
abolishes	NULL
activity	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

62:4173-4184	NULL
.	NULL

Wang	NULL
,	NULL
F.	NULL
,	NULL
C.	NULL
Gregory	NULL
,	NULL
C.	NULL
Sample	NULL
,	NULL
M.	NULL
Rowe	NULL
,	NULL
D.	NULL
Liebowitz	NULL
,	NULL
R.	NULL
Murray	NULL
,	NULL
A.	NULL
Rickinson	NULL
,	NULL
and	NULL
E.	NULL
Kief	NULL
.	NULL

1990	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
latent	NULL
membrane	NULL
protein	NULL
(	NULL
LMP1	NULL
)	NULL
and	NULL
nuclear	NULL
proteins	NULL
2	NULL
and	NULL
3C	NULL
are	NULL
effectors	NULL
of	NULL
phenotypic	NULL
changes	NULL
in	NULL
B	NULL
lymphocytes	NULL
:	NULL
EBNA-2	NULL
and	NULL
LMP1	NULL
cooperatively	NULL
induce	NULL
CD23	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:2309-2318	NULL
.	NULL

Wang	NULL
,	NULL
F.	NULL
,	NULL
H.	NULL
Kikutani	NULL
,	NULL
S.	NULL
Tsang	NULL
,	NULL
T.	NULL
Kishimoto	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1991	NULL
.	NULL

Epstcin-Barr	NULL
virus	NULL
nuclear	NULL
protein	NULL
2	NULL
transactivates	NULL
a	NULL
cis-acting	NULL
CD23	NULL
DNA	NULL
clement	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65:4101-4106	NULL
.	NULL

Whelan	NULL
,	NULL
J.	NULL
,	NULL
P.	NULL
Gbersa	NULL
,	NULL
R.	NULL
Hooft	NULL
van	NULL
Huijsduijnen	NULL
,	NULL
J	NULL
.	NULL

Gray	NULL
,	NULL
G.	NULL
Chandra	NULL
,	NULL
F.	NULL
Talabot	NULL
,	NULL
and	NULL
J.	NULL
F.	NULL
DeLamarter	NULL
.	NULL

1991	NULL
.	NULL

An	NULL
NF-	NULL
«	NULL
B-like	NULL
factor	NULL
is	NULL
essential	NULL
but	NULL
not	NULL
sufficient	NULL
for	NULL
cytokine	NULL
induction	NULL
of	NULL
endothelial	NULL
leukocyte	NULL
adhesion	NULL
molecule	NULL
1	NULL
(	NULL
ELAM-1	NULL
)	NULL
gene	NULL
transcription	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

19:2645-2653	NULL
.	NULL

Yokoyama	NULL
,	NULL
S.	NULL
,	NULL
D.	NULL
Staunton	NULL
,	NULL
R.	NULL
Fisher	NULL
,	NULL
M.	NULL
Amiot	NULL
,	NULL
J.	NULL
Fortin	NULL
,	NULL
and	NULL
D.	NULL
A.	NULL
Thorley-Lawson	NULL
.	NULL

1991	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
Blast-1	NULL
activation/adhesion	NULL
molecule	NULL
and	NULL
its	NULL
identification	NULL
as	NULL
CD48	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

146:2192-2200	NULL
.	NULL

